{
  "responseHeader":{
    "status":0,
    "QTime":0,
    "params":{
      "q":"(Background: melanoma OR Doc_title: melanoma) AND (Background: TP53 OR Doc_title: TP53)"}},
  "response":{"numFound":71,"start":0,"docs":[
      {
        "Meeting_name":" Simultaneous inactivation of TP53 and loss of PTEN diminish response to targeted therapy in V600EBRAF mutant melanoma",
        "Background":"['Numerous cancers are driven by mutationally activated kinases, many of which can be employed to define subsets of cancers and therefore patients most likely to benefit from treatment with rationally designed targeted therapies. Defining the landscape of genetic alterations that participate in cancer transformation provides insight into the diversity of clinical responses observed to targeted treatments. Here, we identified concurrent mutational inactivation of the tumor suppressors TP53 and PTEN as a mechanism of resistance to BRAF inhibitors in melanomas harboring mutant V600EBRAF.Defects in TP53 function and PTEN loss occur in 17% and 12% of malignant melanomas respectively, rendering cells dependent on CHK1 to maintain normal cell cycle progression. We demonstrate that CHK1 inhibition increases sensitivity to a variety of alkylating agents and targeted therapies in V600EBRAF mutant, TP53/PTEN deficient cell lines and patient derived xenografts. Inhibition of CHK1 concurrently with the induction of either DNA damage or replication stress leads to mitotic catastrophe and cell death in our in vitro and in vivo models of TP53/PTEN deficient tumors. In the case of externally applied cellular stress from chemotherapeutics, our results suggest CHK1 inhibition may sensitise this genetically defined subset of melanomas to such treatments.Our results provide some insight into the heterogeneity of clinical outcomes observed when treating BRAF mutant melanomas with BRAF inhibitor and suggest a need for comprehensive screening of TP53 and PTEN inactivation in these patients.']",
        "Doc_id":"AACR_2015-2683",
        "Doc_title":" Simultaneous inactivation of TP53 and loss of PTEN diminish response to targeted therapy in V600EBRAF mutant melanoma",
        "_version_":1606189032922939392},
      {
        "Meeting_name":" Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFNon-V600 (NonV600) mutations (muts).",
        "Background":"['Background', ' Our previous analysis of advanced CM pts and the TCGA demonstrated that BRAFV600 (V600), NRAS, TP53 and BRAFNon-V600 (NonV600) muts are common in CMs. As V600 and NRAS muts are both significantly associated with CM features, we analyzed a large retrospective cohort of CM pts to identify pt, tumor and clinical features significantly associated with TP53 and NonV600 muts. Methods', ' Under an IRB-approved protocol clinical and pathological data were collected for a retrospective cohort of CM pts with clinical molecular testing performed by a next gene sequencing panel from April 2012 to November 2014. Muts were assessed for associations with pt demographics, melanoma characteristics, and clinical outcomes. Significance of observed associations were determined by Fishers exact, Kaplan Meier and log rank testing. Results', ' Among 929 CM pts, 43% had V600, 21% had NRAS, 19% had TP53 and 7% had NonV600 muts. TP53 muts were detected in 11% of pts with V600 muts, 19% of pts with NRAS muts and 29% of pts without V600 or NRAS muts (WT). NonV600 muts were detected in 1% of V600 pts, 4% of NRAS, and 15% of WT. TP53 muts were associated with increased age at diagnosis (p = 0.02) and primary tumor site (p = 0.0001), with increased frequency of head and neck tumor location. Pts with TP53 mut had longer overall survival (OS) from stage IV on univariate analysis (p = 0.04), and on multivariate analysis (p = 0.026) that included gender, stage, and LDH. Improved OS with TP53 mutation was not observed in pts with a V600 mut (p = 0.89), and TP53 mut was not associated with outcomes in V600 pts treated with approved BRAF inhibitors. NonV600 muts correlated with older age at diagnosis (p = 0.005), but no other pt demographic, tumor characteristic, or OS from stage IV. None of the NonV600 mut pts treated with approved BRAF inhibitors (n = 11; 1 with concurrent MEK inhibitor) had an objective response. Conclusions', ' TP53 muts were significantly associated with longer OS from stage IV in this large cohort of CM pts, and should be evaluated other melanoma patient cohorts. BRAF NonV600 mutations were not associated with primary tumor characteristics or OS.']",
        "Doc_id":"ASCO_165238-176",
        "Doc_title":" Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFNon-V600 (NonV600) mutations (muts).",
        "_version_":1606188993048739840},
      {
        "Meeting_name":" Overexpression of miR-3151 leads to direct deregulation of the TP53 pathway and is associated with BRAF mutations in malignant melanoma",
        "Background":"['Background', ' The BRAF gene is the most frequently mutated gene in malignant melanoma (MM). When mutated, it is associated with a more aggressive disease phenotype. Recently, intronic microRNA miR-3151 was identified in intron 1 of BAALC via deep-sequencing of MM samples. BAALC is reported to be the most upregulated gene in BRAF mutated melanoma. In acute myeloid leukemia, both high miR-3151 and BAALC are associated with poor survival. In addition, miR-3151 has direct leukemogenic activity via direct deregulation of TP53.Aims', \" To decipher miR-3151's role in MM carcinogenesis and to elucidate its relation with BRAF mutations.Methods/Results\", ' miR-3151 and TP53 expression levels were determined in MM patients (n=20). Indeed, patients with high miR-3151 had lower TP53 expression. To prove direct downregulation of TP53 by miR-3151, we stably expressed miR-3151 and antagomiR-3151 in MM cell lines (Mel-39, A375, MeWo). RT-PCR and Western blots confirmed downregulation of TP53 by forced miR-3151 expression and upregulation of TP53 by antagomiR-3151. Increased levels of miR-3151 led to increased cell proliferation and decreased apoptosis by miR-3151, whereas antagomiR-3151 reduced cell growth and increased apoptosis. Concurrent Annexin/PI-staining revealed a reduction of cells in S and G2 phase in response to antagomiR-3151. Next, we determined the BRAF mutation status in the set of 20 MM patients and tested for a possible association with miR-3151 expression. BRAF mutated (BRAFmut) patients had a 5-fold higher miR-3151 expression compared to BRAF wild-type (BRAFwt) patients. To test whether BRAF mutations directly influence miR-3151, we performed si-mediated knock-down in BRAFmut cell lines (A375, Mel-39) and introduced the BRAF mutation into the BRAFwt cell line (MeWo) and then determined miR-3151 and TP53 expression. Silencing BRAF decreased miR-3151 expression and consequently increased TP53 expression, while introducing the BRAF mutation increased miR-3151 expression and decreased TP53 when compared to scramble control. Finally, as pharmacologic inhibition of aberrantly activated BRAF is a promising treatment approach for BRAFmut MM and as we had just identified miR-3151 as a downstream target of BRAF, we tested whether simultaneous knock-down of miR-3151 would add to the known effects of the BRAF inhibitor Zelboraf. The presence of antagomiR-3151 reduced the dose of Zelboraf required to achieve cell death by 60%.Summary / Conclusions', ' miR-3151 deregulates TP53 in MM patients, thereby increasing the proliferation of MM cell lines. AntagomiR-3151 reduced MM cell growth and increased apoptosis in vitro. High miR-3151 expression is associated with the presence of BRAF mutations in MM patients, which directly increases miR-3151 expression. Simultaneous treatment of BRAFmut cell lines with the BRAF inhibitor Zelboraf and antagomiR-3151 significantly reduced the IC50 of Zelboraf.']",
        "Doc_id":"AACR_2014-4790",
        "Doc_title":" Overexpression of miR-3151 leads to direct deregulation of the TP53 pathway and is associated with BRAF mutations in malignant melanoma",
        "_version_":1606189022449762304},
      {
        "Meeting_name":" Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991.",
        "Background":"['Activation of CDK4 by amplification, increased expression of Cyclin D1 (CCND1) or reduced expression of the CDK inhibitor p16 (CDKN2A) can contribute to melanocyte transformation, indicating that CDK4 can act as an oncogene in melanoma. We have analyzed the frequency of gene copy number variations (CNV) in the CDK4 pathway and looked for associations of these alterations with patient survival to assess if CDK4 is a viable target for the treatment of human melanoma. In addition, we screened a panel of melanoma cells with a highly selective CDK4/6 inhibitor PD-0332991 (PD-991) and performed gene expression and mutation analysis on these cells to explore possible genomic predictors of sensitivity.Genomic analysis revealed that 75% of primary melanomas had at least one CNV in the CDK4 pathway, with 55% showing a loss of CDKN2A. 28% of melanomas had two or more CNVs and melanomas with two or more CNVs involving CCND1 had worse overall survival (HR 5.56, P=0.02). From the cell line studies low CDKN2A mRNA expression, mutation or loss predicted sensitivity to PD-991 with 23 out of 27 mutant/loss cell lines being sensitive compared to only 3/7 wild type lines (p<0.03). Expression of CDK4, CCND1 or other cyclins or CDK-inhibitors did not predict sensitivity to PD-991. PD-991 induced an increase in both cell size and SA--galactosidase activity that is indicative of a senescent phenotype, and this was associated with cells having wild type p53. In summary, genomic alterations in the CDK4 pathway are frequent in melanoma and are associated with worse survival, particularly when melanomas harbor two or more CNVs involving CCND1. CDK4 inhibition induces a senescent phenotype in melanoma cells that is associated with loss of CDKN2A and wild type TP53. Taken together these data support evaluation of CDK4 inhibitors in melanoma and suggest that CDKN2A and TP53 maybe genomic predictors of sensitivity.']",
        "Doc_id":"AACR_2013-3416",
        "Doc_title":" Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991.",
        "_version_":1606189013606072320},
      {
        "Meeting_name":" Targeted, massively parallel sequencing identifies novel genetic subsets of cutaneous melanoma",
        "Background":"['Despite the prevalence of recurrent, high activating BRAF V600 mutations in 45% of tumors, cutaneous melanoma (CM) is a heterogeneous malignancy resulting from aberrant signaling in multiple pathways. It has been traditionally characterized by activation of the MAPK and PI3K signaling pathways, as well as cell cycle disruption. In recent years, whole-genome and exome sequencing studies have identified several new genes associated with melanomagenesis. However, a comprehensive understanding of concurrent, and mutually exclusive, mutations in tumors is currently lacking. Using a custom targeted capture of 108 genes previously implicated in melanoma pathogenesis, massively parallel sequencing was performed on 94 human melanoma cell lines, 67 patient-derived xenografts (PDX), and 5 cell lines made from PDX, all untreated. Samples were then clustered into groups based on deleterious mutations. 83% of samples had deleterious mutations in the MAPK signaling pathway, including 92 high activity BRAF (55%), 35 RAS codon 61 (21%), 7 with multiple mutations (e.g. low activity BRAF/RAS codons 12/13) (4%) and 10 NF1 (6%) mutated samples. Likely deleterious NF1 mutations were found in several BRAF or NRAS-mutated samples. PI3K pathway mutations were found in 10% of samples, predominantly associated with BRAF mutations. TP53 mutations were found in 24% of samples and were associated with all MAPK signaling mutations. Mutations in chromatin remodeling genes (ARID1A/1B, ARID2, TRRAP, and BAP1) were mutually exclusive with each other and primarily found in tumors with high activity BRAF or NRAS mutations. The majority of BRAF or RAS-mutated samples with a mutation in a chromatin remodeling gene lacked mutations in cell cycle, TP53, and PI3K signaling genes; however, 100% of deleterious, or likely deleterious, NF1-mutated samples with a chromatin remodeling gene mutation harbored additional mutations in cell cycle, TP53, and/or PI3K signaling genes. Of particular interest, five of the 10 NF1-mutated samples (50%) lacked BRAF, RAS, and MEK1/2 mutations but harbored likely deleterious mutations in MAP3K5 or MAP3K9, suggesting the potential involvement of the JNK signal transduction pathway in this particular cohort. Only 4% of samples did not have a deleterious mutation in any of the genes on the panel. These data reveal novel insights into the genetics of melanomas lacking a canonical BRAF V600 mutation. Functional assays are needed to confirm the biological relevance of likely deleterious mutations, which will further facilitate a more thorough classification of CM subsets.']",
        "Doc_id":"AACR_2015-4668",
        "Doc_title":" Targeted, massively parallel sequencing identifies novel genetic subsets of cutaneous melanoma",
        "_version_":1606189021657038848},
      {
        "Meeting_name":" Identification of multiple informative genomic mutations by deep sequencing of circulating cell-free tumor DNA in plasma of metastatic melanoma patients.",
        "Background":"['Background', '  We have been assesseing the prognostic utility of genomic changes in circulating cell-free DNA(cfDNA) in melanoma patients. The limitation has been assessing a few selected genomic targets and sensitivity. The approach of cfDNA analysis in melanoma patients offers detection of potential targeted tumor-related genes mutation(mt) without tumor biopsy.   Methods', '  AJCC stage IV melanoma patients (n=18; different metastasis sites) plasma and  paired metastatic tumor tissues resected after blood draw were assessed.  The assay was performed on 2 ml filtered plasma. We employed Guardant360, a single-molecule digital sequencing assay that enables detection of rare genomic abnormalities with ultra high-specificity and sensitivity. Using bioinformatics and single molecule sensitivity, rare variants could be detected in cfDNA.  Results', '  In an initial 8 patients, BRAF and TP53 in tumor genomic DNA were sequenced. We found ctDNA with somatic mt in 6/8 matched tumor and plasma specimens(mt allele frequency of 0.2-23.1%) with an overall concordance of 86% for the status of BRAF and TP53 mt in a single bleed. To note known BRAFmt at multiple exons were detectable. Subsequently, matched tumor and plasma from 10 patients were analyzed. We found ctDNA mt in 8/10 cases (mt allele frequency of 0.1-19.1%). Well known frequent melanoma-related mt were detected in patients cfDNA(BRAF, TP53). Other known tumor mt were also detected(CDKN2A, NRAS, PTEN, NOTCH1, EGFR, JAK2) that have not been reported. We established the overall concordance of cfDNA mt with metastatic melanomas across all 54 genes and 80kbps to be 49% whereby, individual single gene concordance were significantly much higher.  Conclusions', '  This ongoing study demonstrates that using Guardant360, cfDNA mt can be detected that match with paired melanomas. The approach offers a more comprehensive approach of monitoring metastatic melanoma patients blood for multiple mt during tumor progression. This unique approach will allow for much more comprehensive blood tumor genetic profiling to provide better treatment decision and monitoring for multiple drugable targeted genes without tissue biopsies.']",
        "Doc_id":"ASCO_134589-144",
        "Doc_title":" Identification of multiple informative genomic mutations by deep sequencing of circulating cell-free tumor DNA in plasma of metastatic melanoma patients.",
        "_version_":1606189026833858561},
      {
        "Meeting_name":" Brazilian melanoma genome project",
        "Background":"['Melanoma is the most aggressive form of skin cancer with increasing prevalence in Brazil. The comprehensive molecular profiling of these tumors and the recent genomic classification has improved the knowledge of melanoma biology and foster the identification of potential clinical biomarkers. The aim of this project, as part of the International Cancer Genome Consortium (ICGC) is to perform a genomic profile by whole genome sequencing (WGS) of Brazilian melanomas patients. We reported the WGS using Illumina paired-end sequencing strategy (>30 X-fold coverage) of 66 cases (45% primary and 55% metastatic) and respective matched normal. Overall we observed an average of 46K mutations/genome. The most frequent type of substitutions identified were', ' C>T (22.5%), T>C (6.4%), T>G (4.4%), T>A (2.9%), C>A (2.8%) and C>G (1.7%). A significative difference between frequency of C>T substitutions was observed among histological subtypes, i.e., acral lentiginous (11.3%), nodular (31.2%) and superficial spreading (25.9%). Among the classic genes involved in melanoma biology, we found that 31.8% of patients had BRAF mutations, being the V600E the most frequent (82.6%). A total of 6.1% of patients had NRAS, 3.0% showed KRAS, one case (1.5%) showed HRAS, and 12.1% showed NF1 mutations. TERT promoter mutation (C250T) was found in 28.8% of patients. TP53 mutations found 4.5% and RB1 in 1.5% of cases. Oncogenic KIT and PDGFRA mutations were observed in 6.1%and 1.5%, respectively. BRAF, NRAS, HRAS, KRAS and NF1 mutation were mutually exclusive. BRAF and TERT mutations were significantly more frequent in superficial than acral lentiginous melanomas. We showed that Brazilian melanoma patients exhibit a high number of single mutations and a similar mutation profile to the one reported in other populations. Acral/lentiginous melanoma subtype, which is a common subtype in our setting, showed a distinct mutation frequency. Further analysis will extend to other relevant genes and will also include the study of additional genomes to reach the goal of genomic landscape of 100 Brazilian melanomas cases.']",
        "Doc_id":"AACR_2017-3386",
        "Doc_title":" Brazilian melanoma genome project",
        "_version_":1606188991779962880},
      {
        "Meeting_name":" The genetic evolution of melanoma",
        "Background":"['The pathogenic mutations in melanoma have largely been catalogued, but the order of their occurrence is not known. We identified 82 cases of melanocytic neoplasia with two or more histopathologically distinct precursor and descendent portions. These portions spanned several histopathologic stages including benign nevi, intermediate neoplasms such as dysplastic nevi, melanoma in situ, invasive melanoma, and metastatic melanoma. In total, 277 histopathogically distinct areas were microdissected and sequenced using a panel of several hundred cancer-genes at an average of 275-fold coverage. In all cases precursor lesions harbored mutations known to activate the MAPK pathway, most commonly affecting BRAF or NRAS, and thus these were considered initiating mutations. TERT promoter mutations were the earliest secondary mutations to occur, emerging in intermediate neoplasms and in situ melanomas. Bi-allelic CDKN2A mutations and/or deletions arose predominantly at the transition to invasive melanoma. TP53 and PTEN mutations occurred comparatively later in thicker primary melanomas. In the 12 cases in which matched primaries and metastases were sequenced, no pathogenic mutations were specifically associated with the transition to metastatic melanoma, suggesting that metastatic capability was already present in the primary tumors. Unequivocally benign neoplasms, which mostly consisted of conventional nevi, disproportionately harbored BRAFV600E mutations as the only apparent pathogenic alteration. Lesions that were histopathologically intermediate, such as dysplastic nevi, had two or more pathogenic mutations and were enriched for NRAS mutations. These findings provide genetic support for the existence of an intermediate stage of melanocytic neoplasia, resolving a long-standing controversy. We also found that melanomas with different initiating mutations evolve through distinct evolutionary trajectories linked to specific histopathologic precursors. A mutational signature of UV-radiation-induced DNA damage predominated in lesions from all histopathologic stages, implicating UV-radiation in both the initiation and progression of melanoma. The point mutation burden increased steadily from one progression stage to the next, stabilizing once melanomas became invasive. By contrast, copy number alterations only became prevalent at the transition to invasive melanoma. Melanomas evolve from benign lesions linearly, whereas, they show patterns of branched evolution when they evolve from intermediate lesions; this indicates that evolution may accelerate once a melanocytic neoplasm reaches an intermediate stage. In summary, our study outlines a framework of the genetic evolution of melanocytic neoplasms from precursor lesions and unveils the rate-limiting homeostatic factors that become disrupted as neoplasms progress from one stage to the next, as well as the pathogenic factors driving this evolution.']",
        "Doc_id":"AACR_2016-2372",
        "Doc_title":" The genetic evolution of melanoma",
        "_version_":1606189022741266432},
      {
        "Meeting_name":" Is it what's on the inside that counts? Melanoma mutation profiling and outcomes with immunotherapy",
        "Background":"['Extraordinary advances have been made in the treatment of melanoma over the last few years; immune checkpoint blockade has provided durable responses and meaningful survival outcomes for patients with metastatic disease, yet predicting such responses remains a nascent science. More importantly, the toxicity and financial burden of receiving such therapy warrants a personalized, or precision medicine, approach to appropriate selection of treatment, thus molecular predictors of response may become as important as biomarkers such as PDL1 expression. Recently the high mutational burden of malignant melanoma was shown to be related to the degree of response to the anti-CTLA4 antibody ipilimumab, but mutational burden alone was not sufficient to predict benefit1. Another study has shown NRAS-mutant had a trend to superior outcomes compared with other cohorts in terms of response to therapy with anti-PD1 antibodies and progression-free survival2. Moreover, insight into the molecular evolution of melanoma was recently established3, wherein somatic mutations in oncogenes such as BRAF, NRAS, GNAQ, or GNA11 occur early during progression and additional mutations of TERT, CDKN2A, TP53, and PTEN are seen in late-stage disease. To better evaluate the relationship of these mutations to immunotherapy response, our institution has profiled 95 patients with melanoma with next-generation sequencing (NGS). Of the 95 patients profiled, the most common mutations identified were BRAF (38%), NRAS (21%), TP53 (18%), PTEN (14%), TERT (9%), and CDKN2A (8%). We are presently conducting a retrospective analysis of these selected oncogenes as they relate to clinical responses, and intend to report disease outcomes (duration of response, progression free survival, and overall survival) as they relate to checkpoint inhibition.']",
        "Doc_id":"AACR_2016-1409",
        "Doc_title":" Is it what's on the inside that counts? Melanoma mutation profiling and outcomes with immunotherapy",
        "_version_":1606189024219758593},
      {
        "Meeting_name":" A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairs",
        "Background":"['Melanoma is an aggressive skin cancer of melanocytic origin characterized by high metastatic potential and mutation rate. Affording a survey of the wide breadth of genomic lesions found in melanoma, we present here an analysis of the somatic mutations discovered in the sequenced exomes of 121 melanoma tumor-normal pairs. We identify frequent genomic alterations both in genes previously implicated in melanoma (BRAF, NRAS, TP53, CDKN2A, PTEN) as well as in several genes whose role in melanoma tumorigenesis has not yet been established and thus are of particular interest. To do so we implement a novel method to increase the identification of genes that are significantly recurrently mutated in melanoma in the setting of its exceptionally high mutation rate. A preponderance of C>T transitions (85%) in the observed mutational profile reflects a history of DNA damage due to UV radiation, though the majority of somatic mutations in known melanoma genes are not C>T events. Our study broadens understanding of the genomic lesions involved in melanoma tumorigenesis, and we expect our analysis approach to inform future genomic studies of cancer lineages with similarly high mutation rates.']",
        "Doc_id":"AACR_2012-5056",
        "Doc_title":" A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairs",
        "_version_":1606188988723363840},
      {
        "Meeting_name":" Honokiol inhibits tumor growth in a xenograft melanoma mice model and activates the apoptotic signaling pathway in vivo.",
        "Background":"['Melanoma is the deadliest type of skin cancer. For adults 25-29 years old, melanoma is the most common cancer, while it is the second most common cancer for 15-29 years old. Limited therapies are available for advanced stages; therefore, there is a need for development of new treatments for melanoma.Honokiol is a plant lignan extracted from the magnolia bark tree. Studies from our laboratory showed its chemopreventive effects in a UVB-induced skin cancer model, as well as in vitro pro-apoptotic effects in A431 squamous cancer cells, UACC-62 and SKMEL-2 human melanoma cell lines. In this study, the antineoplastic effects of honokiol were evaluated in vivo against the malignant melanoma cell lines UACC-62 that harbors mutated BRAF, CDK4i, PTEN and SKMEL-2 cells that presents NRAF, and TP53 mutated genes.The present study investigated the mechanism of honokiol-induced antitumoral effects in human melanoma UACC-62 and SKMEL-2 cells in two xenograft melanoma models in mice.UACC-62 and SKMEL-2 melanoma cells were subcutaneously grafted in nude mice, treatment groups received honokiol 50 mg/kg thrice a week and tumor growth was followed. After five to seven weeks, animals were euthanized and tumor tissue collected for gene profiling and western blots. The genetic expression of apoptotic biomarkers was assessed by qRT-PCR by using PCR arrays for the apoptotic pathway (SABiosciences, CA).After subcutaneous grafting of UACC-62 or SKMEL-2 human melanoma cells in the nude mice, the intraperitoneal administration of honokiol at 50 mg/kg body weight for five to seven weeks caused a significant reduction of tumor growth. Honokiol activated the apoptotic pathway in UACC-62 cells xenograft tumors in mice, as attested by the significant up-regulation of BAK1, BAX, CARD8, CASP10, CASP2, CASP6, CASP7, FADD, TNFRSF10B, TNFRSF25, TP53 and TP53BP2 transcripts. In the western blots from the UACC-62 cells tumors, there was an increase in the expression of CASP3, CASP7, CASP8, CASP6, cleaved CASP6 and CASP10 proteins in the honokiol treated group. In the tumors originated from the SKMEL-2 melanoma cells, a significant up-regulation of BAD, BAK1, BAX, NOD1, CARD6, CASP7, FADD, TNFRSF21 and TRAF3 transcripts was observed. The activation of the apoptotic pathway in the SKMEL-2 cells tumors by honokiol was further confirmed by western blots in the tumor lysates, where it was observed an increase in the activation of caspases and cleavage of PARP in the honokiol treated animals.Honokiol treatment exerted significant antitumor effects, including the activation of the apoptotic signaling pathway in UACC-62 and SKMEL-2 human melanoma cells in xenograft tumors in mice. These findings suggest that honokiol is a good candidate for further studies as a treatment for malignant melanoma.This work is supported by a Translational Cancer Center Research Grant, funded as 2010 Research Initiative Center by the State of South Dakota.']",
        "Doc_id":"AACR_2013-5555",
        "Doc_title":" Honokiol inhibits tumor growth in a xenograft melanoma mice model and activates the apoptotic signaling pathway in vivo.",
        "_version_":1606188998982631424},
      {
        "Meeting_name":" Mutation and chemosensitivity profiling of 18 human melanoma cell lines",
        "Background":"['Malignant melanomas account for a substantial proportion of cancers worldwide and are largely resistant to conventional therapy. The heterogeneity and the invasiveness of melanomas present notable challenges for anti-cancer treatment. Recently, several mutations in RAF, RAS, and PTEN were identified that allow for prognosis of cancer development and progression. Therefore, inhibitors of the RAF-MEK-ERK pathway form attractive candidates for molecular-based targeted treatment of melanoma cancer. Here, we present the molecular characterization and chemosensitivity profiling of 18 human melanoma cell lines. Eight of these were established by Oncotest from human tumor xenografts originally derived from primary patient material. The molecular profiling included mutational analysis for BRAF, PIK3CA, KRAS, NRAS, TP53, and PTEN by sequencing. The chemosensitivity profiles were determined in vitro using a fluorescence-based cytotoxicity assay and included commonly used chemotherapeutic agents for treatment of melanoma, targeted agents (sorafenib and bortezomib) and various BRAF (PLX-4032, PLX-4720, GDC-0879) and MEK (CI-1040, PD0325901) inhibitors. The clinically relevant BRAF V600E substitution was the most prevalent mutation and was found in more than 50% of the melanoma cell lines. The chemosensitivity profiling revealed diverse patterns of selectivity and potency with mean IC50 values between 0.4 nM (vinblastine) and 8.3 M (carboplatin). Each of the BRAF inhibitors tested was clearly more active in melanoma cell lines carrying a BRAF mutation. On average, IC50 values of BRAF inhibitors were more than 20-fold lower for the BRAF V600E mutated cell lines compared to the wild type cell lines. However, the BRAF mutated cell line MEXF 462NL was resistant towards BRAF inhibitors and it is warranted to compare its gene expression profile and mutational status with BRAF mutated cell lines responding to BRAF inhibitors. By using an ex vivo clonogenic assay, similar activity patterns for BRAF inhibitors were found, with mutated BRAF tumor xenografts showing markedly higher sensitivity. Potential synergistic activity of BRAF inhibitors with other inhibitors of the RAF-MEK-ERK pathway or with standard chemotherapeutic agents will be presented. The mutational status of selected cancer related genes, as well as responsiveness towards many cytotoxic and targeted agents was analyzed for 18 melanoma cell lines. This extensive genotypic and phenotypic characterization makes this melanoma cell line panel a valuable tool for in vitro profiling of novel compounds, in particular inhibitors of the RAF-MEK-ERK pathway.']",
        "Doc_id":"AACR_2012-4170",
        "Doc_title":" Mutation and chemosensitivity profiling of 18 human melanoma cell lines",
        "_version_":1606189001260138496},
      {
        "Meeting_name":" Discovery of ABI-231 analogs targeting the colchicine site in tubulin for advanced melanoma",
        "Background":"['We previously discovered a novel 2-aryl-4-benzoyl-imidazole (ABI) scaffold exerts its potent anti-proliferative effects through interacting with the colchicine binding site in tubulin. Extensive structure-activity relationship (SAR) studies of this novel scaffold showed that the best analog in this series, ABI-231, has an average IC50 = 5.2 nM against panels of melanoma and prostate cancer cell lines, is orally bioavailable, and strongly suppress melanoma tumors in vivo. Analyses of the potential binding pose of ABI-231 at the colchicine binding pocket suggested small substitutions to the indole moiety in ABI-231 could further increase its interactions to tubulin.Based this hypothesis, we have established an efficient synthetic method for the synthesis of ABI-231 analogs by either rotating the indole ring or introducing substituents on the indole of ABI-231. Using this method, we synthesized and tested 27 analogs of ABI-231. Several of the compounds show excellent potency against a panel of melanoma cancer cell lines with a diverse genomic background (mutations in BRAF, TP53, CDKN2A and PTEN) that are frequently encountered in clinical metastatic melanoma tumors. Additionally, they are not substrates for the P-glycoprotein (Pgp) efflux pump and therefore strongly inhibited the multidrug resistant cell lines. The potency of the compounds was further verified by their potent growth inhibition of cancer cell colonies. Results from cell cycle analysis, apoptosis evaluation and tubulin polymerization inhibition are consistent with their expected mechanisms of action. Potential off-target analyses performed by Eurofins Cerep-Panlabs SafetyScreen 44 indicated that they are clean and does not inihibt any of the tested off-targets at 100 fold of its IC50 value in melanoma cells, suggesting the good safety profile for this compound and the probably these scaffold in general. We are currently performing in vivo efficacy studies for the most potent analogs. These compounds hold great promise as a new generation of orally available tubulin inhibitors.']",
        "Doc_id":"AACR_2016-4848",
        "Doc_title":" Discovery of ABI-231 analogs targeting the colchicine site in tubulin for advanced melanoma",
        "_version_":1606189031167623168},
      {
        "Meeting_name":" The effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), on BRAF wild-type melanoma.",
        "Background":"['Background', ' E7080 is a TKI targeting VEGFR1-3, FGFR1-4, KIT, RET and PDGFR. Anti-tumor activity has been observed in melanoma patients in phase I. This study examines the mode of action of E7080 in preclinical melanoma models  Methods', '  Mutational status of 18 genes (9 RTKs, 7 oncogenes and 2 tumor suppressor genes) was determined in 14 human melanoma cell lines.  Gene profile and biomarkers of anti-angiogenesis and anti-tumor activity of E7080 were investigated in vitro and in vivo by gene expression analysis in a melanoma cell line panel and in human melanoma tissues.  Results', '  18 types of mutation (mu) were found among 9 RTKs in ten of 14 melanoma cell lines. 2 mu of BRAF, 9 mu of TP53, 3 mu of PTEN, 2 mu of CDKN2a and 1 mu of NRAS were also found among 9, 9, 3, 2 and 1 melanoma of 14 cell lines, respectively. 4 of the 5 melanoma with BRAF wild type (wt) were the most sensitive to E7080 in mouse xenograft models, while 5 of the 6 with BRAFmu/PTENwt were the most resistant,  suggesting 3 sub-groups for sensitivity to E7080 based on BRAF/PTEN status', ' 1; BRAFwt/PTENwt, 2; BRAFmu/PTENmu and 3; BRAFmu/PTENwt. % of pericyte-covered tumor vessels was 25%, 29% and 35% among 3 sub-groups, respectively. Anti-tumor activity of E7080 was correlated to % of pericyte coverage in groups 1 and 2, in which  tumor vessels are sensitive to E7080. DNA microarray analysis demonstrated decreased FGFR1-4 expression in BRAFmu melanoma, while qPCR analysis showed that FGFR2 and FGFR3 expression were significantly higher in BRAFwt than BRAFmu in human melanoma tissues. E7080 inhibited in vitro proliferation of BRAFwt melanoma, which overexpressed FGFR3. Knockdown of FGFR3, FRS-2a, NRAS and AKT-3 genes with siRNA transfection inhibited proliferation of E7080-sensiteve melanoma.  Conclusions', '  BRAF/PTEN mutation status was associated with pericyte coverage of tumor vessels and the expression of FGFR1-4 in a panel of melanoma cell lines. E7080 showed superior anti-tumor activity against BRAFwt melanoma, in which the type of tumor vessels was sensitive to angiogenesis inhibition by E7080 and a subgroup of which were dependent on FGFR3 signaling.']",
        "Doc_id":"ASCO_78644-102",
        "Doc_title":" The effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), on BRAF wild-type melanoma.",
        "_version_":1606189028850270208},
      {
        "Meeting_name":" AMPK induction, lysosomal acidification and melanoma survival increased by p53 dysfunction are counteracted by inhibiting autophagy",
        "Background":"['BACKGROUND. In contrast to the majority of human tumors which harbour p53 mutations, melanomas preferentially have BRAF V600E or NRAS(Q61K) mutations accompanied by dysfunction of the p53 tumor suppressor gene, which may help progression from nevi to invasive melanoma. Although ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53 (Viros A. et al, Nature. 2014;511', '478-82), some evidences for an anomalous wt p53 response to radiation in melanomas are a dysfunctional pro-apoptotic DNA damage response which can be enhanced by radiation sensitizers like halogenated pyrimidines (Rieber M, Rieber MS.Cancer Biol Ther. 2008;7', '1561-6), and a report that p53 knockdown in melanoma cells resulted in decreased proliferation (Avery-Kiejda KA1, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, Talseth-Palmer BA, Rizos H, Zhang XD, Scott RJ, Hersey P.BMC Cancer. 2011;11', '203) .PURPOSE. Since activation of AMPK by AMP inhibits ATP-consuming metabolic pathways during metabolic stress which may cause autophagy, we investigated the possible role of melanoma p53 status in modulating response to AMPK activators and autophagy inhibitors, in physiological 5mM glucose. EXPERIMENTAL. Genetically-matched NRAS-mutant human melanoma cells with unequal p53 mutational status were exposed to different glucose levels in the presence of AMPK inducers including autophagy modulators. Formation of autophagic vesicles were quantitated by cytometric red/gree acridine orange fluorescence Apoptosis-associated PARP cleavage was studied by specific immune blotting. RESULTS. AMPK induction in response to AICAR was greater than that of metformin and was increased in mutant p53 cells, which also showed greater resistance to autophagy inhibition. Greater AMPK activation correlated with increased lysosomal acidification in mutant p53 cells. CONCLUSIONS. Our results identify a role for a) p53 dysfunction in enhancing the response to AMPK activators and autophagy to favour tumor cell survival, b) autophagy inhibitors in counteracting pro-survival AMPK signaling.']",
        "Doc_id":"AACR_2015-2907",
        "Doc_title":" AMPK induction, lysosomal acidification and melanoma survival increased by p53 dysfunction are counteracted by inhibiting autophagy",
        "_version_":1606189025332297728},
      {
        "Meeting_name":" Novel small molecule CRM1 inhibitors induce nuclear accumulation of p53, phosphorylated ERK and apoptosis in human melanoma cells.",
        "Background":"['Inhibition of nuclear export can promote re-activation of tumor suppressor proteins (TSPs) by restoring them to the nucleus. CRM1 (chromosome region maintenance 1, XPO1) is the exclusive exporter of many TSPs. We hypothesized that CRM1 inhibition can be used as a therapeutic target in melanoma. The growth inhibitory and pro-apoptotic effects of KPT-185, KPT-276 and KPT-330, potent, small molecule, selective inhibitors of nuclear export (SINEs) were evaluated in a panel of human metastatic melanoma cell lines using an MTS assay and Annexin V/PI staining, respectively. The weak CRM1 inhibitor, KPT-185 trans-isomer, and DMSO vehicle were controls in all assays. CRM1 protein was expressed in melanoma cell lines regardless of molecular profile (BRAF, NRAS, TP53) as determined by immunoblot. SINEs inhibited cell growth in a concentration-dependent manner and induced apoptosis at nanomolar concentrations (range=139.7nM - 2.41M). Both BRAF wild type (WT) and BRAF V600E mutant lines were sensitive to apoptosis by SINE, but BRAF V600E lines had an 8.8-fold lower IC50s as compared to BRAF (WT) lines (p=0.018). The cytostatic and pro-apoptotic effects of CRM1 inhibition were associated with nuclear accumulation of p53, and p21 induction in A375 and CHL-1 melanoma cell lines with functional p53 at time points prior to apoptosis, while pERK accumulated in melanoma cells regardless of p53 status. In pharmacokinetic studies in mice, KPT-276 and KPT-330 showed >50% oral bioavailability with Cmax >5M. Mice bearing either A375 (BRAF V600E) or CHL-1 (BRAF WT) melanoma xenografts were given KPT-276 or KPT-330 SINE by oral gavage. A375 xenografts (p<0.0001 for both drugs) and CHL-1 xenografts (p=0.0087 and 0.0002 respectively) showed significant growth inhibition as compared to vehicle-treated controls with good tolerability. KPT-330 is currently in Phase 1 clinical trials in patients with advanced cancers including melanoma as the first orally bioavailable, SINE CRM1 antagonist.']",
        "Doc_id":"AACR_2013-3443",
        "Doc_title":" Novel small molecule CRM1 inhibitors induce nuclear accumulation of p53, phosphorylated ERK and apoptosis in human melanoma cells.",
        "_version_":1606188992260210688},
      {
        "Meeting_name":" p53 is differentially regulated in proliferative and invasive melanoma cells",
        "Background":"['Melanoma is one of the few cancer types where p53 is not often mutated. Cancers which have not mutated TP53, often attenuate p53 activity by affecting upstream regulators or downstream effectors of p53. As melanoma progresses, it by passes senescence, proliferates, and switches from a proliferative phenotype to a more invasive phenotype. We have found that invasive melanomas, characterized by high levels of the pro-invasive Wnt molecule, Wnt5A, express active p53. Conversely, melanomas with a more proliferative phenotype, characterized by increased MITF signaling and low Wnt5A expression, do not express active p53. We show that the expression of p53 appears to be controlled by Wnt5A, and this may occur via CAMKII. By Western blot, we have observed that more proliferative melanoma cells express a high molecular weight p53 (250 kDa). This high molecular weight p53 does not break down on an SDS-PAGE gel. Knocking down p53 in proliferative and invasive melanoma cells, using siRNA, decreases the high molecular weight band in the proliferative cells, and the 53 kDa band in the more invasive cells. When we over express HA-tagged p53 in proliferative cells, we see multiple bands for p53 by Western blot, including the high molecular weight bands, suggesting that p53 is being post-translationally modified in these cells. We confirmed that ubiquitination is involved in the formation of the high molecular weight p53, by treating proliferative cells with SMER3, an E3 ligase inhibitor. Following two hours of treatment, the high molecular weight p53 band decreased and this decrease persists for 16 h. Next, we transfected an E6 ligase into invasive melanoma cells, which express active p53. Expression of the E6 ligase increased the expression of the high molecular weight p53 band (250 kDa), but these cells also continued to express active p53 (53 kDa). To determine if ubiquitination is targeting p53 for degradation in proliferative cells, we treated invasive and proliferative cells with MG132, a proteasome inhibitor. Following treatment with MG132, p53 (53 kDa) increased in invasive cells, suggesting that p53 is degraded via the proteasome in these cells. However, when we treated proliferative cells with MG132 we did not see an increase in the high molecular weight band, suggesting that p53 is not being degraded via the proteasome in these cells. By immunofluorescence, we found that p53 is in the cytoplasm of proliferative cells, suggesting that ubiquitination may be playing a role in sequestration of p53 in proliferative cells. In invasive cells, p53 remains largely nuclear, and we demonstrate that this plays critical roles in response to therapy, counter-intuitively driving resistance, by allowing cells to undergo an adaptive stress response that we term pseudosenescence']",
        "Doc_id":"AACR_2015-3775",
        "Doc_title":" p53 is differentially regulated in proliferative and invasive melanoma cells",
        "_version_":1606189001418473472},
      {
        "Meeting_name":" Exome sequencing of desmoplastic melanoma reveals recurrent NFKBIE promoter mutations and diverse MAPK/PI3K pathway activating mutations",
        "Background":"['Desmoplastic melanomas (DMs) comprise 4% of the overall melanoma burden and have a 5-year survival rate of 85%. DMs are dermal tumors characterized by spindled melanocytes situated within abundant desomplastic stroma. These unusual histological features commonly lead to misdiagnosis. Currently, there are no known genetic drivers. A better understanding of the underlying biology of desmoplastic melanoma would provide biomarkers and therapeutic opportunities. Towards this goal, we performed low-coverage genome and high-coverage exome sequencing of 20 DMs in a discovery cohort, followed by targeted sequencing of 293 candidate genes on a validation cohort of 42 cases. Additionally, high-resolution aCGH was performed on samples from both cohorts. A high mutation burden (median 62 mutations/Mb) ranked desmoplastic melanoma among the most highly mutated cancers sequenced to date. Mutation patterns strongly indicate that UV-radiation is the dominant mutagen and implicate a superficially located cell of origin despite their predominantly intradermal presentation. Novel alterations included recurrent promoter mutations and amplification of NF-kappa B inhibitor epsilon, NFKBIE (IkB) in 14.5% of samples. The promoter mutations typically affect both alleles and occur over a highly conserved DNA region. The mutations are predicted to disrupt a canonical Ets Like Factor 1 (ELF1) binding site. In total, these data imply aberrant NF-kappa B signaling as a pathogenic feature of desmoplastic melanoma. Commonly mutated oncogenes in melanomas, in particular BRAF V600E and NRAS Q61K/R, were absent. Instead, other genetic alterations known to activate the MAPK and PI3K signaling cascades were identified in 73% of samples, affecting NF1, CBL, ERBB2, MAP2K1, MAP3K1, BRAF, EGFR, PTPN11, MET, RAC1, SOS2, NRAS, and PIK3CA. Rb and p53 pathway alterations occurred respectively in 71% and 66% of tumors, affecting RB1, FBXW7, CDK4, PPP6C, CCND1, CDKN2A, TP53, and MDM2. Finally, TERT promoter mutations or amplifications occurred in 90% of tumors. The consequences of the mutations on protein expression levels was confirmed by immunostaining for NF1, EGFR, Rb, CDK4, CCND1, p16, p53, and Mdm2. Collectively, many of these oncogenic mutations are potentially druggable. In conclusion, desmoplastic melanomas harbor distinct genetic alterations that explain their unique biology, and this study illuminates genetic biomarkers and nominates targets for therapeutic intervention.']",
        "Doc_id":"AACR_2015-2968",
        "Doc_title":" Exome sequencing of desmoplastic melanoma reveals recurrent NFKBIE promoter mutations and diverse MAPK/PI3K pathway activating mutations",
        "_version_":1606188997834440704},
      {
        "Meeting_name":" Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.",
        "Background":"['Background', ' Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by a dense fibrous stroma, resistance to chemotherapy and no actionable driver mutation for targeted therapy. We investigated the efficacy of PD-1/L1 inhibitors and correlation with genetic landscape and tumor immune microenvironment in DM. Methods', ' Retrospective analysis of 1054 pts with melanoma treated with anti-PD-1/L1, resulting in 57 pts with unresectable or metastatic DM. Available baseline biopsies were analysed by digital quantitative immunohistochemistry (IHC) for CD8 and PD-L1 and by whole exome sequencing (WES), compared to available tissue from non-DM pts treated with anti-PD1/L1 at UCLA. Results', ' At a median follow up of 20 mo, 40 pts (70%, 95% CI 57-82) had an objective response by RECIST 1.1 criteria, including 18 (45%) CRs with no relapse observed to date. Responses were similar in DM subsets (23 pure, 29 mixed and 5 indeterminate). Kaplan-Meier estimated 1-year and 2-year overall survival were 85% (95% CI 78-98) and 74% (95% CI 64-89). WES revealed a median of 1282 (interquartile range 517-1692) non-synonymous somatic mutations per tumor in DM tumors (n = 17), significantly higher (p = 0.02) than the median of 462 (interquartile range 230-1150) in non-DM (n = 23). Mutations in NF-1 were the most common (13/17) followed by loss-of-function TP53 and ARID2, and > 82% of single nucleotide mutations were UV damage signatures. IHC analysis from 19 DM and 13 non-DM revealed a strikingly higher percentage of PD-L1 positive cells in the tumor parenchyma in DM (p = 0.04), highly associated with CD8 density and PD-L1 expression in the tumor invasive margins, indicating an active adaptive immune response. No genetic mechanisms known to cause constitutive PD-L1 expression were detected in these samples. Conclusions', ' Patients with advanced DM derive significant clinical benefit from PD-1/L1 inhibitors, likely related to the high mutational burden and a highly active adaptive immune response as the main mechanism of immune escape prior to therapy. Our results challenge the general conception that dense fibrous stroma around the malignant cells interferes with immune cell infiltration and efficacy of immunotherapy.']",
        "Doc_id":"ASCO_185186-199",
        "Doc_title":" Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.",
        "_version_":1606188979037667328},
      {
        "Meeting_name":" Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.",
        "Background":"['Background', ' Vemurafenib, dabrafenib and tremetinib are FDA approved for treating BRAFV600-mutated melanoma. Vemurafenib has activity in non-melanoma BRAFV600-mutated tumors, as well. Unfortunately, most patients acquire resistance to BRAF monotherapy and mechanisms of resistance remain unknown. Methods', ' We analyzed CLIA certified clinical next generation sequencing data from BRAFV600E mutated non-melanoma tumors treated with BRAF inhibitor (BRAFi) from May 2012 to January 2016. We evaluated co-occurring genomic alterations and progression-free survival (PFS) of each patient. Results', ' Of the 30 patients treated with BRAFi monotherapy, 11 (37%) had NSCLC, 5 (17%) had colorectal cancer, 4 (13%) had cholangiocarcinoma, 3 (10%) had thyroid cancer, 3 (10%) had Erdheim Chester disease, and the remaining 4 (13%) had salivary gland carcinoma, glioblastoma, gliosarcoma, or unknown primary. Two of the 5 colorectal cancers were treated with BRAFi plus cetuximab. Three subsets of co-occurring genomic alterations were identified', ' 14 patients (47%) had no co-occuring alterations, 5 (17%) had PI3K/PTEN/mTOR pathway alterations, and 11 (37%) had other mutations', ' TP53 (n = 11), SMAD4 (n = 4), LKB1 (n = 2) and IDH (n = 2). Eight patients have ongoing response without progression on BRAFi monotherapy (PFS 222-805 days). Six of 8 responders (75%) have no co-occurring alterations, 2 of 8 (25%) have other mutations. All patients with co-alterations in the mTOR pathway progressed within 77 days. Tumors with mTOR pathway aberrations had a significantly lower median and mean PFS (mPFS, 53 days) compared to tumors with other co-occurring mutations (mPFS 206 days) and tumors without co-alterations (mPFS 276 days) (p = 1.03e-05). Conclusions', ' Co-occurring genomic alterations may help predict response to BRAFi therapy in BRAF-mutated tumors and PI3K/PTEN/mTOR pathway mutations may contribute to de novo resistance. Next generation sequencing is warranted on all BRAF mutated tumors as are further studies to address whether concurrently targeting co-occurring alterations will improve PFS. A trial combining BRAFi + mTOR inhibitor is underway (NCT01596140).']",
        "Doc_id":"ASCO_164352-176",
        "Doc_title":" Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.",
        "_version_":1606189003868995584},
      {
        "Meeting_name":" Oncogenic BRAF fusion induces MAPK-pathway activation targeted by MEK inhibitor and phosphatidylinositol 3-kinase inhibitor combination treatment in mucosal melanoma",
        "Background":"['Background', ' Although remarkable progress has been made in the genomic characterization of cutaneous melanoma, the genetic alterations of primary mucosal melanoma (PMM) remain largely unknown. This study aims to investigate the recurrent mutations in PMM and to characterize the oncogenic potential of the newly identified ZNF767-BRAF fusion as well as its therapeutic implications in PMM.Methods', ' A total of 46 PMMs underwent exon-capture sequencing of 111 cancer-associated genes to identify somatic non-synonymous mutations, copy number alterations, and structural variations. A cancer cell with a novel ZNF767-BRAF fusion was established from a patient with PMM of the respiratory tract, who was refractory to vemurafenib. To characterize the oncogenic functions of the novel ZNF767-BRAF fusion, we performed western blot, soft agar growth assay and in vivo tumor. The inhibitory effects of vemurafenib, trametinib, buparlisib and LEE011 monotherapy and their combination treatment were measured in vitro and in vivo.Results', ' Targeted exon-capture sequencing of 46 PMMs revealed a total of 48 somatic non-synonymous mutations in 26 genes. Eight genes harbored recurrent mutations on NRAS (n = 6; 13%) and TP53 (n = 4; 9%) along with BRAF, KIT, MAP3K9, C8A, KRAS, FGFR3 (all observed in two cases; 4%). Of note, a novel ZNF767-BRAF fusion was identified in a PMM of the respiratory tract refractory to vemurafenib treatment. ZNF767-BRAF fusion was validated by Sanger sequencing. We show that ZNF767-BRAF encoded protein promotes the dimerization of RAF and potently activates mitogen-activated protein kinase pathway. The ectopic expression of ZNF767-BRAF fusion induced tumor formation as shown in colony forming assay and tumor xenograft model. The treatment of trametinib inhibited the growth of PMM cells harboring the ZNF767-BRAF fusion but vemurafenib showed no inhibitory effects. Compared with either agent alone, the combination of trametinib and buparlisib showed synergistic antitumor effects in vitro and in vivo.Conclusions', ' The genomic makeup of PMM is remarkably diverse and distinct from that of cutaneous melanoma. BRAF fusion defines a new molecular subset of PMM and can be therapeutically targetable by the combination of MEK inhibitor and PI3K Inhibitor.']",
        "Doc_id":"AACR_2015-3942",
        "Doc_title":" Oncogenic BRAF fusion induces MAPK-pathway activation targeted by MEK inhibitor and phosphatidylinositol 3-kinase inhibitor combination treatment in mucosal melanoma",
        "_version_":1606189020769943553},
      {
        "Meeting_name":" Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations.",
        "Background":"['Background', ' Somatic mutations in IDH1 or IDH2 genes are prevalent in diverse solid tumors and implicated in tumorigenesis. Therapeutic responses to IDH inhibitors are infrequent plausibly due to presence of simultaneous alterations activating compensatory molecular pathways. Methods', ' We retrospectively reviewed results from clinical genomic profiling with targeted next-generation sequencing in two independent data sets of archival formalin-fixed paraffin-embedded (FFPE) tumor samples (Ion Torrent < 50 genes, 300; FoundationOne < 343 genes, 30; Oncomine 128 genes, 4) and plasma liquid biopsies (Guardant360 < 73 genes panel, 337 samples) from patients with solid tumors of all stages. Results', ' In 334 FFPE samples the most represented cancers were gliomas (50%), melanomas (14%), cholangiocarcinomas (11%), and non-small cell lung cancer (NSCLC, 6%). In 296 IDH1-mutated FFPE samples the most frequent simultaneous alterations were in TP53 (45%), BRAF (11%), KRAS (9%), and PIK3CA (26, 9%). In the most represented IDH1-mutated tumor types commonly altered genes were TP53 (66%) in gliomas, BRAF (53% [V600K/R 30%, V600E 19%]) in melanomas, PIK3CA (13%), CDKN2A (13%) in cholangiocarcinomas and KRAS (65%) in NSCLC. In 38 IDH2-mutated FFPE samples the most frequent simultaneous alterations were in TP53 (32%), and KRAS (16%). In 337 plasma samples the most represented cancers were NSCLC (39%), cholangiocarcinoma (13%), and breast cancer (8%). In 172 IDH1-mutated plasma samples the most frequent simultaneous alterations were in TP53 (40%), KRAS (23%), EGFR (16%) and BRAF (16%). In the most represented IDH1-mutated tumors commonly altered genes were TP53 (48%), KRAS (37%) in NSCLC and TP53 (37%), KRAS (24%), BRAF (18%) in cholangiocarcinoma. In 161 IDH2-mutated plasma samples the most frequent simultaneous alterations were in TP53 (43%), EGFR (20%), and KRAS (19%). In the most represented IDH2-mutated tumors commonly altered genes were TP53 (43%), EGFR (32%), KRAS (18%) in NSCLC and TP53 (18%), ESR1 (18%), KRAS (18%) in breast cancer. There were 4 tumors with IDH1 and IDH2mutations. Conclusions', 'IDH1 and IDH2 mutations often coexist with simultaneous oncogenic alterations including these in potentially druggable molecular targets.']",
        "Doc_id":"ASCO_183678-199",
        "Doc_title":" Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations.",
        "_version_":1606189031636336640},
      {
        "Meeting_name":" Effects of honokiol on UACC-62 and SKMEL-2 melanoma cell lines",
        "Background":"[\"Honokiol is a plant lignan extracted from the magnolia bark tree, previous studies from our laboratory showed its chemopreventive effects in a UVB-induced skin cancer model, as well as pro-apoptotic effects in A431 squamous cancer cell line. Studies from other groups have reported antineoplastic effects in different cancer models as well. In this study, the antineoplastic effects of honokiol were evaluated in vivo and in vitro against UACC-62 cell line that harbors mutated BRAF, CDK4i, PTEN and against SKMEL-2 cell line that presents NRAF, and TP53 mutated genes. For the in vivo studies, nude male mice were injected subcutaneously with 5x106 UACC-62 or SKMEL-2 cells. The next day animals were randomized into control and treatment groups, each group containing 20 animals. The control group received 250 l of sesame oil intraperitoneally (IP), the treatment groups received honokiol dissolved in sesame oil; 1.25 mg (IP) in the UACC-62 group and 50 mg/kg (IP) in the SKMEL-2 injected mice. Animals were treated three times a week, for 5-7 weeks. Tumors incidence, multiplicity and volume were recorded every three days, mice's weights and external signs of toxicity were also closely monitored. Tumor tissues were collected for histopathology, Western blots, and PCR arrays. For the in vitro studies, both cell lines were evaluated for cell viability, proliferation, apoptosis by TUNEL assay, cell cycle arrest by propidium iodide staining, and Western blots for proteins expressions. Honokiol treatment significantly reduced (p<0.05) tumor volumes in both xenograft experiments. No evident signs of toxicity were observed in the honokiol treated animals. In both cell lines, honokiol significantly decreased (p<0.05) cell viability and proliferation, honokiol caused cell cycle arrest in Go/G1 phase in UACC-62 cell line, while it caused accumulation of cells in the G2/M phase in SKMEL-2 cell line; honokiol significantly increased the DNA fragmentation in both cell lines. Honokiol strongly decreased the expressions of cyclin D1, cyclin D2 and cyclin B1 while increasing the cleavage of caspase 3, caspase 8, caspase 9 and PARP in both cell lines. In UACC-62 honokiol decreased the expressions of CDK2, CDK4, cyclin E, cdc2p34 and p21. In SKMEL-2, honokiol decreased the expression of CDK4, PCNA and increased the expression of p21. These findings suggest that honokiol is a good candidate for further studies as a treatment for malignant melanoma. This work is supported by a Translational Cancer Center Research Grant, funded as 2010 Research Initiative Center by the State of South Dakota.\"]",
        "Doc_id":"AACR_2012-3809",
        "Doc_title":" Effects of honokiol on UACC-62 and SKMEL-2 melanoma cell lines",
        "_version_":1606189011612729345},
      {
        "Meeting_name":" Cumulative cancer risk in the NCI Li-Fraumeni Syndrome Cohort",
        "Background":"['Background', 'Li-Fraumeni Syndrome (LFS) is a rare hereditary cancer predisposition syndrome characterized by the early onset of a wide range of cancers and a very high lifetime cumulative cancer risk. Despite significant progress in understanding LFS, uncertainty remains regarding the cancer incidence rates and cancer spectrum for TP53 mutation carriers. In addition, the cancer incidence for members of families meeting the clinical diagnostic criteria of LFS or Li-Fraumeni like (LFL) syndrome but in which no TP53 mutation has been identified (TP53- families) has not been established.Methods', \" The NCI's LFS Study (NCT01443468) is a natural history study that opened to accrual in August 2011. Inclusion criteria include LFS or LFL syndrome; a germline TP53 mutation; or a personal history of choroid plexus carcinoma, adrenocortical carcinoma (ACC), or 3 primary cancers. Participants complete a detailed family history and individual information questionnaires. Confirmation of all reported cancer diagnoses is pursued.Results\", ' Of the 122 families enrolled to date, 95 families have a germline TP53 mutation (TP53+ families) and 27 are TP53-families.TP53+ families', ' 243 mutation carriers from 95 mutation-positive families were included in the cancer risk estimates. The cumulative risk to first cancer diagnosis for the entire group is 43% by age 30 and close to 100 by age 70, with males having higher risk in childhood adolescence and females having higher risk starting in the 20s, mostly due to breast cancer. When examined by cancer type, the cumulative risk to age 70 is 35% for breast cancer, 16% for soft tissue sarcoma, 10% for brain cancer, 7% for bone cancer, 2% for leukemia, 2% for ACC, and 26% for others. Overall survival is approximately 80% by age 50.TP53- families', ' The underlying etiology contributing to cancer risk in the TP53- families is not known at this time; therefore, for the estimation of cancer risk among these families, we included all bloodline members belonging to the lineage contributing to the eligibility criteria. Among the 522 individuals from the 27 TP53- families, the cumulative risk to first cancer diagnosis is 7% by age 30 and 45% by age 70. The lifetime cumulative risk is higher for breast, brain, lung cancer, and melanoma compared with other cancer types. Overall survival is approximately 90% by age 50.Conclusion', ' We report the cumulative cancer incidence and overall survival among TP53 mutation carriers in TP53+ families as well as among members of TP53- families. Identification of additional causative gene(s) in TP53- families will help refine the cancer risk of family members. We are evaluating the risks of second primary cancers, and whether the rate is dependent on the type of the first cancer in all families.']",
        "Doc_id":"AACR_2015-2749",
        "Doc_title":" Cumulative cancer risk in the NCI Li-Fraumeni Syndrome Cohort",
        "_version_":1606189039150432256},
      {
        "Meeting_name":" Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).",
        "Background":"['Background', ' Large sequencing studies in MCM have shown a TP53WT incidence of approximately 80%. In preclinical TP53WT melanoma models, the oral p53-MDM2 inhibitor AMG 232 exhibited synergistic, cytotoxic-type antitumor activity when combined with MAPK inhibitors. This phase 1 study assessed the toxicity (CTCAE 4.03), maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary antitumor activity (RECIST 1.1) of AMG 232 plus trametinib (T) and dabrafenib (D) (BRAFV600-mutant) or T (BRAFV600-WT) in pts with TP53WT MCM. Methods', ' Using 3+3 dose escalation design, pts with advanced TP53WT (using a CLIA-approved assay) MCM received AMG 232 PO QD for seven days of each 3-week cycle (7/21) at 120, 240, or 480 mg plus either T 2 mg PO QD and D 150 mg PO BID (Arm 1; BRAFV600-mutant) or T 2 mg QD (Arm 2; BRAFnonV600-mutant). Results', ' At the time of this analysis, 21 pts (median age, 58 y [range 2476]; male, n = 11; at least 2 systemic treatments, n = 15) were treated. Arm 2 enrolled first', ' AMG 232 120 mg (n = 6), then 240 mg (n = 6). Due to chronic grade (G) 2 gastrointestinal toxicity, an intermediate dose (180 mg; n = 3) was determined as the preliminary MTD. Arm 1 enrolled at AMG 232 120 mg (n = 4), then 180 mg (n = 2). The most common reasons for AMG 232 withdrawal were disease progression (n = 8) and AEs (n = 4); 6 pts remain on AMG 232. All 21 pts had treatment-related AEs (TRAEs); the most common TRAEs were nausea (n = 18), fatigue (n = 17), diarrhea (n = 14), and vomiting (n = 13). The only DLT (Arm 2; 240 mg) was G 3 pulmonary embolism. Preliminary PK analysis suggests that AMG 232 exposure (area under the curve) is similar to that as monotherapy at the same dose, with no apparent drug-drug interaction between AMG 232 and T; analysis of D and T PK is ongoing. Of 21 pts, 6 had partial response (Arm 1/2, n = 4 [67%]/2 [13%]), 13 had stable disease (Arm 1/2, n = 2 [33%]/11 [73%]), and 2 progressed (Arm 1/2, n = 0/2 [13%]) as best response; 17 had tumor reduction (Arm 1/2, n = 6 [100%]/11 [73%]). Conclusions', ' In this population of pts with MCM, AMG 232 combined with D and/or T during DE was tolerable up to 180 mg QD 7/21 days, showing an acceptable PK profile and early antitumor activity. Clinical trial information', ' NCT02110355']",
        "Doc_id":"ASCO_181299-199",
        "Doc_title":" Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).",
        "_version_":1606189004936445952},
      {
        "Meeting_name":" Phase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma",
        "Background":"['Background', ' The poor activity of treatments (tt) against metastatic melanoma (MM) mainly relies in the absence of predictive markers of efficacy that could allow selection of responsive pts. This phase I/II clinical trial of sorafenib (S) + temozolomide (T) was done with an intense translational research program in order to evaluate both safety and efficacy and to identify early markers of treatment benefit. Methods', ' 63 pts with MM were included in the dose-escalating phase I (n = 15) and the phase II (n = 48). Sequential blood and tumor samples were harvested to study baseline parameters and intra-individual variations of biomarkers during the treatment. Tumor sequencing of 44 exons in 12 genes were done in 37 pts. CGH arrays, RNA expression profiling, immunostaining (P-ERK, P-MEK and Ki67) were performed at d0 and 21. Functional imaging using dynamic contrast enhanced ultrasonography (DCE-US) was performed at days 0, 7, 15, and every month. Results', ' 54 pts were treated at the MTD', ' 400 mg of S bid and 150 mg/m2 of T every other week. Half of them had received  2 lines of prior chemotherapies and 37% had high LDH. Median number of cycles was 4 (1-22). Toxicity was manageable and required tt interruption for only 3 pts. On 49 evaluable pts, 4 had PR (8%), 19 SD (39%) and 26 PD (53%) for a treatment benefit in 47%. Six months PFS and overall survival rates were respectively 15.2% and 60.6%. DCE-US functional imaging parameters before treatment, at day 7 or day 15 were significantly associated with tt efficacy (OR or SD vs. PD) at 2, 4 or 6 months (p < 0.05). NKG2D ligand, soluble MICA, was found in 80% of pts with PR or SD vs. 3% of PD pts and was also significantly associated with clinical benefit (p < 0.05). On 37 tumors tested, mutations were found in BRAF (62%), STK11 (25%), NRAS (8%), TP53 (6%) CDKN2A (3%), CTNNB1 (3%) without correlation to clinical response. CGH array and RNA expression profiling results are pending. Conclusions', ' This study confirms the safety and efficacy of the association of S and T in pts with MM. Translational research identified early markers associated with treatment benefit that could allow selection of patients for more personalized and efficient treatment.']",
        "Doc_id":"ASCO_52830-74",
        "Doc_title":" Phase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma",
        "_version_":1606189037533528064},
      {
        "Meeting_name":" Ultraviolet radiation cooperates with individual oncogenes to drive melanomagenesis through distinct molecular mechanisms",
        "Background":"['The contribution ultraviolet radiation (UVR) makes to genetically distinct melanoma subtypes is unclear. Melanoma driven by oncogenic BRAF or oncogenic NRAS differ in their epidemiological, clinicopathological and genetic features. NRAS melanoma in humans occurs in older individuals and presents at sites most exposed to UVR damage such as the head and neck.In this study we show excessive sun exposure and NRAS-driven melanoma can co-occur by juxtaposing the epidemiological, clinical and genetic characteristics of a G12DNRAS-driven human melanoma case subject to extreme UVR exposure. To model the interaction of UVR with specific oncogenes and mimic human disease, we used mouse melanoma models driven by V600EBRAF or G12DNRAS. We previously reported that UVR cooperates with V600EBRAF by targeting the tumour suppressor TP53. In this study we confirm that UVR cooperates with G12DNRAS to drive melanoma and, as observed in humans, murine UVR-G12DNRAS melanoma occurs in older animals that accumulate higher lifetime exposure to UVR. Furthermore, we find murine UVR-G12DNRAS melanomas are histologically and genetically heterogeneous, and distinct to UVR-V600EBRAF murine and human melanomas. UVR-G12DNRAS melanomas present more UVR-induced mutations, a longer latency to tumour development and secondary driver mutations distinct from UVR-V600EBRAF melanoma. We investigated whether UVR cooperates equally with other RAS isoforms, and exposed G12DKRAS animals to UVR. These animals presented a different latency to melanoma development and specific cooperating secondary targets distinct from UVR-V600EBRAF and UVR- G12DNRAS. This implies that different RAS isoforms activate oncogenic pathways differently. Critically, UVR-V600EBRAF, UVR-G12DNRAS, UVR-G12DKRAS tumors present similar mutation rates when UVR exposure is held constant, which suggests that the differences in tumour latency might be explained if melanomas driven by different oncogenes require varying numbers of subsequent co-operators.Finally, we present preclinical evidence showing how targeting the UVR-induced mutations found in the long tail of UVR-related mutations in NRAS melanoma can provide therapeutic options for NRAS mutant melanoma patients.The insight gained begins to provide a molecular explanation for distinct associations between UVR and individual oncogenes in melanomagenesis, and we show how UVR-induced damage can be exploited to stratify patients for personalised therapy approaches.']",
        "Doc_id":"AACR_2016-4167",
        "Doc_title":" Ultraviolet radiation cooperates with individual oncogenes to drive melanomagenesis through distinct molecular mechanisms",
        "_version_":1606189026359902208},
      {
        "Meeting_name":" Contribution of heterozygous loss of ribosomal protein L5 as general tumor suppressor in cancer.",
        "Background":"['The association between ribosome defects and cancer became clear with the recent discovery of somatic mutations in ribosomal protein genes in several cancers, such as lymphoid leukemias and glioblastoma (Nat Genet. 2013 Feb;45(2)', '186-90 & Blood. 2016 Feb 25;127(8)', '1007-16 & Nature. 2014 Jan 23;505(7484)', '495-501). To further delineate the role of ribosomal proteins in human cancer, we systematically screened the TCGA database for genetic lesions in ribosomal protein genes, confirmed the contributing capacity of the most common somatic ribosomal protein defect in cancer pathogenesis by molecular interference, and explored the mode of action of this ribosomal protein defect. Systematic analysis of TCGA mutation and copy number data of respectively 4926 and 7322 patients representing 16 cancer types for defects in all 81 ribosomal protein genes. After stringent filtering, six ribosomal protein encoding genes (RPL5, RPL11, RPL23A, RPS5, RPS20 and RPSA) were significantly altered and identified as candidate cancer driver genes. RPL5 was located at a significant peak of heterozygous deletion on chromosome 1p22 and showed significant mutations and deletions in 11% of glioblastoma (GBM), 28% of melanoma, 34% of breast cancer (BRCA), and in 20% of multiple myeloma cases, thereby supporting heterozygous RPL5 inactivation to be the most common somatic ribosomal protein defect in human cancer. Human specific RPL5 doxycycline inducible knockdown (sh-hRPL5) in TP53 WT and TP53 mutant human breast cancer cell lines (MCF7 and MDA-MB-231) and in a TP53 mutant human glioblastoma cell line (U-118 MG) proved that RPL5 knockdown accelerated in vivo tumor progression in NSG mice. This acceleration was associated with reduced phosphorylation of CDK1tyr15, which is required for cell cycle progression from G2 to mitosis. Whereas RPL5 has been implicated in TP53 and MYC regulation, no consistent effects of RPL5 downregulation on these proteins could be detected in TP53 WT and TP53 homozygous R280K mutant breast cancer models (sh-hRPL5). Interestingly, partial RPL5 inactivation was found to be associated with PTEN protein suppression in these tumors. This observation was confirmed in various cell models; in normal mouse neural stem/progenitor cells and mouse bone marrow cells (RPL5+/lox by INF and poly I', 'C), and also in GBM cancer pre-disposition mouse neural stem/progenitor cell model (sh-mRPL5 TP53 -/-). RPL5 downregulation also accelerated tumor formation in the PTEN deficient GBM cell line U-118 MG, underscoring undefined PTEN-independent mechanisms of RPL5. Overall, we identified RPL5 as a new tumor suppressor that shows heterozygous inactivation in 11-34% of multiple human cancer types. Partial molecular inactivation of RPL5 supported a tumor suppressor function for RPL5 in accelerating breast cancer and glioblastoma progression in vivo, which may be, in part, due to a new function of RPL5 in regulating PTEN.']",
        "Doc_id":"AACR_2017-1546",
        "Doc_title":" Contribution of heterozygous loss of ribosomal protein L5 as general tumor suppressor in cancer.",
        "_version_":1606188998155304960},
      {
        "Meeting_name":" Mutation yield of a 34-gene next-generation sequencing test in community-based tumor samples.",
        "Background":"['Background', '  Several targeted therapies have been approved for treatment of solid tumors. Identification of gene mutations associated with response to these targeted therapies is rapidly progressing. We developed and validated a 34-gene next-generation sequencing (NGS) panel and used this to test community-based samples sent for routine molecular testing for actionable gene mutations.  Methods', '  A laboratory-developed NGS test on an Ion Torrent PGM sequencer was used to determine mutation profiles for 121 consecutive, de-identified FFPE tissue samples collected from patients diagnosed with  melanoma (n = 31), lung (n = 27), colorectal (n = 33), and breast cancer (n = 30). NGS results were compared to those of the routine single-gene molecular tests.  Results', '  Twenty-four (20%) samples had mutations detected by the originally requested tests, all of which were also detected by NGS. However, NGS detected at least 1 additional mutation not detected by the original test in 92 (76%) of the 121 samples. Of the additional mutations detected, 16 were actionable according to NCCN guidelines (3 BRAF [2 V600E and K483Q]in melanoma specimens; 2 KRAS  [A146T and L19F], 2 BRAF [2 V600E] and 1 NRAS [Q61K] in colorectal cancer; and 2 EGFR [E746-A750 and R680Q] and 6 KRAS [A146T, G12C, G12V, Q22K, G12A and G13C] in lung cancer). Most of the additional mutations detected by NGS were in regions not covered by the routine molecular test(s); in the other cases, NGS may have provided greater sensitivity than the routine test. Overall, mutations were detected in 21 of the 34 genes included in the NGS panel, 17 of which were detected in multiple tumor types. The most frequently mutated gene was TP53 (64/121), but 83% (100/121) of the specimens harbored mutations in at least 1 gene other than TP53.  Conclusions', '    This NGS assay frequently detected actionable mutations not identified by routine single-gene tests. These findings suggest that broader mutation profiling of solid tumors, as with the 34-gene NGS mutation panel, could provide additional information for treatment selection in a substantial proportion of cases.']",
        "Doc_id":"ASCO_152287-156",
        "Doc_title":" Mutation yield of a 34-gene next-generation sequencing test in community-based tumor samples.",
        "_version_":1606188977557078016},
      {
        "Meeting_name":" A national platform for molecular diagnostics",
        "Background":"['Background', '  Increasing demand for testing multiple markers for targeted therapies requires a platform to incorporate molecular diagnostics in the normal pathway of care. This programme was planned to demonstrate the applicability of a nationwide platform of testing, linked to healthcare records in a central database.  Methods', '  From 8/2011 to 6/2013, patients with breast, colorectal, prostate, lung or ovarian cancer, or melanoma, were approached at 26 hospitals for consent to centralised molecular testing of routine biopsies. Formalin-fixed paraffin-embedded sections were forwarded with peripheral blood samples to 3 technical hubs for analysis of a small panel of abnormalities by Sanger sequencing, pyrosequencing or similar mathods, and fluorescent in-situ hybridisation for chromosomal structural changes.  Results were transmitted directly to clinical centers for inclusion in medical records. A routine clinical dataset was collected from all patients using the national cancer registration system.  Results', '  10,754 patients (98% of those approached) consented to analysis of  material, with 9010 samples sent for analysis. Of 1,889 lung cancers, 35% had at least one abnormality, only 0.65% had more than one. kRAS was most often mutated (26%), followed by EGFR (8.3%), Alk rearrangement (1.9%) and BRAF (1%).  In 1634 colorectal cancers, 47% had one abnormality, 30% two and 3% three. Commonest abnormalities were mutated TP53 (25%), double mutated TP53 and kRAS ( 17%),  kRAS only (17%) and BRAF (5%).  In 535 melanomas there were 42% BRAF mutants, 22% NRAS mutant and only 2.4% with double abnormalities. There was  heterogeneity between the laboratories in turnaround time and failure rate, especially for non-standard analyses. A multiplex next-generation sequencing (NGS) panel was piloted for samples collected in the last 3 months of the programme, showing high levels of concordance in comparison to conventional sequencing.  Conclusions', '  A broad system of molecular diagnostics is feasible and highly acceptable to patients. The efficiency is improved with NGS analysis, and the system is now being used to support prescreening of patients with lung cancer for entry into a multiarm study of novel therapeutics.']",
        "Doc_id":"ASCO_135175-144",
        "Doc_title":" A national platform for molecular diagnostics",
        "_version_":1606189023591661568},
      {
        "Meeting_name":" Elephant p53 (EP53) expression induces apoptosis of human cancer cells.",
        "Background":"['The goal of our study was to determine if elephant TP53 (EP53) proteins contributing to increased apoptosis and possible cancer resistance in elephants could translate into human cancer cells as a future effective cancer treatment. We previously reported that elephants have a lower than expected rate of cancer, 20 copies of TP53 (1 ancestral gene with introns [EP53-anc] and 19 retrogenes [EP53-retro1-19]), and increased p53-mediated apoptosis induced by DNA damage in elephant cells compared to human cells (Abegglen JAMA 2015). For the current study, we expressed various EP53 proteins in human cancer cells with different p53 status, including osteosarcoma (U2-OS, Saos-2), glioblastoma (T98G), and breast cancer (MCF7). Western blot analysis confirmed EP53 expression. We compared apoptosis in the human cancer cells transfected/transduced with negative control vectors vs. epitope or protein-tagged EP53 exposed to doxorubicin (to induce DNA damage). Apoptosis was measured by cell viability, caspase activity, Propidium Iodide/Annexin V staining, and fluorescence microscopy. We observed a significant increase in caspase activity (normalized to cell viability) of U2-OS and T98G cells expressing EP53 compared to negative control treated cells as shown in Table 1, and apoptosis with p21 restoration in Saos-2. In U2-OS, which overexpress MDM2, EP53 was more effective at inducing apoptosis compared to human TP53. Taken together, we found that EP53-anc restored p53-mediated apoptosis and EP53-anc / EP53-retro9 enhanced p53-mediated apoptosis. These data suggest for the first time that EP53 functions in human cancer cells to promote cell death. Ongoing efforts are exploring the EP53 mechanism of action that leads to increased apoptosis, including expression of EP53 in additional cancer types (lung, melanoma, colon, prostate, and others) with a variety of genetic backgrounds to characterize its functional context. These results support the further exploration of EP53-based cancer therapeutics.']",
        "Doc_id":"AACR_2017-2153",
        "Doc_title":" Elephant p53 (EP53) expression induces apoptosis of human cancer cells.",
        "_version_":1606189033070788608},
      {
        "Meeting_name":" Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in pts (pts) referred for phase I trials.",
        "Background":"['Background', '  Plasma from pts with cancer contains cell free DNA (cfDNA) that can be interrogated by next generation sequencing (NGS). We assessed the use of plasma NGS as a multi-purpose biomarker in advanced cancer pts referred for Phase I trial participation.  Methods', '  Between 12/2012 and 12/2013, the plasma of pts with known mutations in tumor biopsies completing at least 2 courses of investigational targeted drug therapy was collected monthly until disease progression. cfDNA was extracted and NGS performed on the PGM platform with the Ion AmpliSeq Cancer Hotspot Panel v2 starting from 10ng of DNA. This panel amplifies 207 amplicons covering 2,800 COSMIC mutations from 50 oncogenes and tumor suppressors.  Results', '    The mean sequencing coverage across the experiments was 1,685x. Overall, 37 pts (colon (n=11), ovary (10), breast (7), bladder (2), kidney (2), glioblastoma (2), endometrium/melanoma/penile/lung (n=1) receiving inhibitors of the PI3K-AKT-mTOR pathway (n=23), MEK (n=7), PARP (n=3)) or others targets (n=4) were included. TP53, KRAS and PIK3CA were the most commonly mutated genes in tumor biopsies. At Phase I trial initiation (C1D1), 20 of 37 pts (54%) had at least one mutation identified in cfDNA. Pts with only nodal or peritoneal disease were less likely to have a mutation detected', ' 1/6 (17%) having a cfDNA mutation. Thirty-six different mutations were identified at C1D1 in 20 pts', ' TP53 (n=15) with an allele frequency (AF) ranging from 2% to 57%; KRAS (n=6; AF 4-51%); PIK3CA (n=6; AF 5-58%); APC (n=4; AF=15-33%); SMAD4, HRAS, FBXW7, CDKN2A, ATM (n=1). Three mutations identified in cfDNA were not identified in tumor', ' TP53 (Y220C; AF 4.5%), ATM (R337C; AF 18%), TP53(R342fs*2; AF 23%). In 15 pts, subsequent AF mutation monitoring showed that 75% (3/4) of pts with a >30% decrease in AF at C2D1 compared to baseline had stable disease or a partial response by RECIST after 2 cycles. Conversely 87.5% (7/8) of pts with an increasing AF >20% at C2D1 had progressive disease by RECIST after 2 cycles, while a stable AF at C2D1 (-20%< AF <+30%)   was associated with SD in 2/3 pts.  Conclusions', '  NGS of plasma is feasible even with low DNA input and may be of utility as a predictive and response biomarker.']",
        "Doc_id":"ASCO_129717-144",
        "Doc_title":" Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in pts (pts) referred for phase I trials.",
        "_version_":1606189004888211456},
      {
        "Meeting_name":" Genomic analysis and 3-y efficacy and safety update of COMBI-d",
        "Background":"['Background', ' Previous analysis of COMBI-d (NCT01584648) showed that D+T compared with D monotherapy improved ORR (69% [95% CI, 62%-75%] vs 53% [95% CI, 46%-60%]; P = 0.0014), reduced risk of progression (HR, 0.67 [95% CI, 0.53-0.84]; P = 0.0004) and death (HR, 0.71 [95% CI, 0.55-0.92]; P = 0.0107), and increased 2-y OS rate (51% vs 42%) in BRAFV600mutant melanoma. Methods', ' In this phase 3, randomized, double-blind study, pts with histologically confirmed unresectable stage IIIC or IV, BRAF V600E/Kmutant melanoma were randomized 1', '1 to receive frontline D 150 mg twice daily (BID) + T 2 mg once daily or D 150 mg BID only. The primary endpoint was PFS; secondary endpoints were OS, ORR, duration of response, and safety. Whole-exome sequencing was used to assess somatic mutations and copy number changes in pretreatment tumor (mean target coverage [MTC], 170) and matched normal blood samples (MTC, 100) collected from > 140 pts to further characterize BRAF V600mutant melanoma and explore whether individual gene changes or genetic profiles were associated with treatment benefit. Results', ' A total of 423 pts were randomized to D+T (n = 211) or D (n = 212). As expected, initial genetic analysis of 130 pts showed that BRAF was the most frequently mutated gene (V600E, 83%; V600K, 15%). Additional mutations were observed in genes related to tumor suppression (TP53, PTEN, CDKND2A) and resistance to MAPK pathway inhibition (MEK1, MEK2, NRAS, NF1, RAC1), and amplifications were observed in BRAF and MITF. Overall mutation rate was higher in V600K vs V600E pts (median mutations per sample, 1701 vs 419; P< 0.0001). Updated genomic analysis, including OS and mutation rate association, and efficacy and safety results, including 3-y OS, will be presented. Conclusions', ' Preliminary genetic analyses showed additional mutations related to tumor suppression and MAPK inhibitor resistance were present in pts with BRAF-mutant melanoma, with a higher overall mutation rate in V600K-mutant tumors. Updated genetic analysis and 3-y efficacy and safety analysis will be presented. Clinical trial information', ' NCT01584648']",
        "Doc_id":"ASCO_168199-176",
        "Doc_title":" Genomic analysis and 3-y efficacy and safety update of COMBI-d",
        "_version_":1606189036992462848},
      {
        "Meeting_name":" Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).",
        "Background":"['Background', ' SCLC and L-LCNEC are aggressive neoplasms that are both associated with smoking history and are thought to overlap in clinical, histogenetic, and genomic features. We reviewed the genomic profiles of >1187 patients to assess the genomic similarities of these diseases. Methods', ' Comprehensive genomic profiling (CGP) of tumors from 300 L-LCNEC and 887 SCLC patients in the course of clinical care was performed to suggest pathways to benefit from therapy. Results', ' Commonly altered genes in both diseases included TP53, RB1, MYC/MYCL1, MLL2, LRP1B and PTEN; alterations in other genes occurred at somewhat differing frequencies (table). For both diseases, RB1 mutation significantly co-occurred with TP53 mutations (p<0.001), but occurred in a mutually exclusive fashion to STK11 and CDKN2A (p<0.001). RB1 was mutually exclusive with KRAS for L-LCNEC but not for SCLC. The interquartile range for SCLC and L-LCNEC TMB is 7.9 and 12.6 with the 75% quartile being 14.4 and 17.1 respectively. Cases of both diseases will be presented with radiographic response to genomically matched targeted therapy and immunotherapy, particularly in cases of high TMB. Conclusions', ' Given the similar overall genomic profiles and clinical behavior of a subset of these diseases, they could be conceived of as a single disease to be further classified by genomically defined classes such as SCLC-type (TP53/RB1mutated) and NSCLC-like (wild type for one or both). By analogy to NSLC and melanoma, benefit from immunotherapy appears most likely for only the upper quartile of cases in TMB. GeneL-LCNECSCLCFrequency (% altered)TP5372.390.9RB137.769.5CDKN2A15.03.3MYC14.76.0PercentileTMB (mutations/Mb)25th percentile4.56.3Median9.99.975th percentile17.114.4']",
        "Doc_id":"ASCO_182716-199",
        "Doc_title":" Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).",
        "_version_":1606189031928889344},
      {
        "Meeting_name":" A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.",
        "Background":"['Background', ' About 50% of tumors harbor inactivating mutations in TP53. Aberrant MDM2 signaling is an alternate mechanism to inactivate wild type (WT) p53. In preclinical studies, DS-3032b disrupted the MDM2-WTp53 interaction resulting in cell cycle arrest, senescence and/or apoptosis. We characterized the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetic and pharmacodynamic (PD) profiles and efficacy of DS-3032b in a phase 1 trial. Methods', ' Using accelerated and Bayesian design in the dose-escalation phase of this 2-part study (part 1), we escalated DS-3032b from 15 to 240 mg orally once daily (QD) on a continuous or interrupted (QD 21/28 days) schedule. Results', ' Thirty-one of 34 pts enrolled in part 1 were evaluable for dose-limiting toxicities (DLTs). Median age was 59.5 years, 44% male, and 62% had  3 prior therapies. The majority of pts (79%) had wt TP53 and the most frequent tumor type was well/de-differentiated liposarcoma (LPS; n = 15). MTD was 120 mg (interrupted) and 90 mg (continuous) schedule. The most common drug-related adverse events were hematologic and gastrointestinal. Six pts had DLTs, 5 were due to thrombocytopenia alone or with neutropenia. Of 26 pts evaluable for efficacy, none had an objective response but 77% had stable disease (SD); consistent with cell cycle arrest/senescence seen in preclinical studies. Tumor shrinkage was seen but did not meet RECIST criteria. Two pts with previously progressing LPS and carcinoid remain on study for 26+ mos and tumor sequencing showed MDM2 gene amplification. Exposures of DS-3032b were significantly higher in pts with lower body weight. Induction of MIC- 1 (PD biomarker of WT p53 reactivation) correlated with drug exposure. Conclusions', ' DS-3032b has an acceptable safety profile at the MTD of 120 mg (QD 21/28). Clinical benefit with durable SD was seen in tumors with aberrant MDM2 signaling and WT p53. MDM2 is universally amplified in LPS and TP53 is the most commonly mutated gene in cancer; warranting further investigation of DS-3032b. Pts with melanoma or diffuse large B-cell lymphoma (DLBCL) are being enrolled in 2 dose-expansion cohorts (part 2) at the tentative recommended phase 2 dose 120 mg QD 21/28. Enrollment is ongoing (NCT01877382). Clinical trial information', ' NCT01877382']",
        "Doc_id":"ASCO_166204-176",
        "Doc_title":" A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.",
        "_version_":1606189031103660032},
      {
        "Meeting_name":" RNA turbulence by tumor type",
        "Background":"['Background', ' Overexpression of mRNA provides an oncogenic mechanism, downstream of DNA level changes detected by sequencing, that can be treated with targeted therapies. It is still unknown why a subset of patients experience substantial responses to targeted therapies, while others experience minimal benefit. We hypothesize that the occurrence of multiple mRNA drivers may segment by cancer type in a similar manner to mutation burden. Methods', ' We examined results from 2088 patients with the 23 most common histologies that had received molecular testing at Paradigm Diagnostics by a panel of 56 mRNA targets, including 21 from the MAPK pathway, 14 from the P53 pathway, and 18 from the PI3K pathway. We calculated RNA turbulence, defined as the number of mRNA overexpressed in each case, as well as the pathway-specific RNA turbulence for the MAPK, PI3K and TP53 pathways. Results', ' Significant differences in overall and pathway-specific RNA turbulence across cancer types was observed. Colon and rectal cancers had high turbulence in the MAPK and TP53 pathways, with 87% having multiple putative drivers in the MAPK pathway and 29% having multiple drivers in the PI3K pathway. Small cell lung cancer and kidney cancers had high turbulence in the PI3K pathway, with 33% and 39% having multiple RNA drivers respectively. Overall, pancreatic, kidney and colon cancers had the highest turbulence and GIST, melanoma and cholangiocarcinoma had the lowest. There was a slight inverse relationship in tumor type when ranked by mutation burden vs. RNA turbulence Conclusions', ' RNA turbulence represents a unique mechanism by which to analyze tumors and correlates with disease type. Multiplex diagnostics assaying DNA, RNA, and protein level tumor changes will likely be needed to guide cancer therapeutics.']",
        "Doc_id":"ASCO_194868-199",
        "Doc_title":" RNA turbulence by tumor type",
        "_version_":1606188970927980544},
      {
        "Meeting_name":" Comparative molecular analyses of BRAF-V600E mutant tumors",
        "Background":"['Background', ' Little is known about the molecular characteristics of BRAF mutant (mt) CRC. It is unknown whether BRAF mt CRC have molecular and biological profiles similar to BRAF mutant melanomas (Mel). Methods', ' A total of 5139 tumor samples (CRC, 4007 and Mel, 1132) submitted to Caris Life Sciences for IHC (protein expression), ISH (gene amplification), and NGS sequencing between 2009 and 2015 were retrospectively studied. Chi-square tests determined differences. Results', ' The rate of BRAF-V600E mutation was 7% in CRC (n = 270), and 30% in Mel (n = 334). Most frequently co-mutated genes in BRAF mt CRC were TP53 (56%), APC (26%), and PIK3CA (19%), and most frequently overexpressed proteins were TOP2A (90%), EGFR (77%), and cMET (57%). Most frequently co-mutated genes in BRAF mt Mel were CDKN2A (28%), ROS1 (19%), and TP53 (13%), and most frequently overexpressed proteins were PD1+ TILs (75%), and TS (71%). When compared with BRAF mt Mel, BRAF mt CRCs had a greater frequency of TP53 (56% vs. 13%), APC (26% vs. 3%), PIK3CA (19% vs. 1%), and SMAD4 (18% vs. 0%) mutations (all p-values < 0.01); however, mutations in CDKN2A (28% vs. 19%) and ROS1 (19% vs. 12%) appeared at higher rates in mt Mel (statistical significance not reached). BRAF mt CRC had a higher frequency of P-glycoprotein (PGP) (52% vs. 9%), cMET (57% vs. 13%), EGFR (77% vs. 6%), and HER2 (4% vs. 0%) overexpression (all p-values < 0.001), but lower PD1+ TILs (61% vs. 75%; p = 0.012) and ERCC1 (17% vs. 41%; p = 0.004) when compared with mt Mel. Co-occurring RAS mutations were rare, seen in 3 CRC and 2 Mel pts. MEK1 (1/31) and MEK2 (1/31) mutations were detected only in Mel. Mismatch repair deficiency and MSI were seen in 34% of BRAF mt CRC. On examining PD1+ TILs and PDL1 tumor expression in MSI-high (H) and MSIstable (S) CRC, and comparing with Mel, PD1+ TILs were found in 75% of Mel, 80% of MSI-H CRC, and 56% of MSI-S CRC (Mel or MSI-H CRC vs. MSI-S CRC; p < 0.01). PDL1 was positive in 10% of MSI-H and 15.8% of MSI-S CRC and 15% of Mel. Conclusions', 'BRAF mt CRCmay carry molecular alterations that are distinct from BRAF mt Mel, suggesting different carcinogenic pathways, and potential resistance mechanisms. Drug combinations that target these alterations (e.g., cMET, EGFR) may warrant further investigation.']",
        "Doc_id":"ASCO_169294-176",
        "Doc_title":" Comparative molecular analyses of BRAF-V600E mutant tumors",
        "_version_":1606189034023944192},
      {
        "Meeting_name":" Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment.",
        "Background":"['Background', '  The knowledge of actionable somatic genomic alterations present in each tumor is making possible the era of personalized cancer treatment.  Methods', '  Using massively parallel sequencing we performed whole exome sequencing analysis of tumor and matched normal blood samples of 8 patients (2 pancreatic adenocarcinoma, 1 neuroendocrine tumor, 1 glioblastoma, 1 uveal melanoma, 1 colon cancer) to identify putatively actionable tumor specific genomic alterations. We used 2 in silico methods (Polyphen and SIFT) to estimate the functional significance of a given confirmed mutation.  Primary xenografts (PDX), generated by direct engraftment of tumor samples from the patients into immunocompromised mice, were used as an in vivo platform that provided the opportunity to test proposed personalized medicine strategies.  Results', '  At this time exome sequencing analyses have been performed for 5 patients (1 patient died prematurely, 1 tumor sample was insufficient, 1 result is pending).  More than 30 million bases of target DNA were analyzed in the tumor and normal samples in every case, with at least 70 distinct reads at each base. Tumor specific mutations (Muts) and copy number variations (CNVs) were identified', ' 5 Muts in the neuroendocrine tumor; 62Muts/6CNVs and 38Muts/10CNVs in the pancreatic tumors; 63Muts/23CNVs in the glioblastoma; 5 Muts in the melanoma. All samples profiled contained actionable alterations with the most relevant mutations affecting NF1, PTPN11, EPHA3, CDKN2A, FAS (glioblastoma); PI3KCA, ARID1A, ARID1B, DDR2, SMAD4, TP53, KRAS, PTCHD3 (pancreatic); CREB3L3, ITPR2 (neuroendocrine); GNA11, TAOK3 (melanoma). PDX from the pancreatic cancer patient was treated with a PI3K inhibitor and dasatinib, reported to be effective in discodin domain receptor 2 (DDR2) mutant cancer with no effect.  Accordingly treatment of that patient with dasatinib was not effective and the level of this mutation in the tumor was observed to be low.  Conclusions', '  Detection of actionable tumor-specific genomic alterations in the clinical setting is feasible. In silico methods and primary xenografts can help in the challenge of linking confirmed mutations to protein function and ultimately to clinical utility.']",
        "Doc_id":"ASCO_98611-114",
        "Doc_title":" Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment.",
        "_version_":1606189012991606784},
      {
        "Meeting_name":" Clinical next-generation sequencing to identify actionable alterations in a phase I program.",
        "Background":"['Background', '   Due to affordable high-throughput technologies Clinical Laboratory Improvement Amendments (CLIA)-certified next-generation sequencing platforms for genomic characterization have emerged. Given the expansion of molecularly-targeted therapeutics, there is a huge opportunity to use genomic testing for patient selection in clinical trials. We sought to determine the frequency of alterations across tumor histologies in patients with advanced cancer using a deep sequencing approach to assess for mutations in hotspot regions of 46 cancer-related genes.    Methods', '  We examined data from the first 500 patients with advanced cancer prospectively enrolled on an IRB-approved protocol through the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center. Archival tumor DNA was tested for hotspot mutations in 46 genes (Ampli-Seq Cancer Panel) using an Ion Torrent PGM Sequencer (Life Technologies, CA) at the clinical molecular diagnostics laboratory. The data were analyzed using R Statistical Software (R Foundation for Statistical Computing, Vienna, Austria).   Results', '  Patients with 38 tumor types were enrolled. Of 500 patients analyzed, 293 had at least one detectable mutation. The most commonly mutated genes were TP53 (38%),  KRAS (11%), and PIK3CA (10%).  Of tumor types tested (n  10), sarcoma (20%) and kidney (30%) had the fewest alterations, while pancreas (100%), colon (91%) and melanoma (87%) had the highest proportion. 46 patients had both primary tumors and metastases analyzed; of mutations seen in primaries or metastases, 91% were seen in both. Across all samples, there was a strong pattern of mutual exclusivity between TP53 mutations and PIK3CA mutations. Alterations in potentially actionable genes were detected in 291 (58%) patients. Both rare mutations in common tumor types and potentially actionable (directly/indirectly druggable) mutations in rare tumor types were identified.  Conclusions', '   Implementation of multiplex testing in the CLIA environment facilitates genomic characterization across multiple tumor types to identify novel opportunities for genotype-driven trials. Matching patients to molecularly targeted therapies is underway.']",
        "Doc_id":"ASCO_131570-144",
        "Doc_title":" Clinical next-generation sequencing to identify actionable alterations in a phase I program.",
        "_version_":1606189031604879360},
      {
        "Meeting_name":" Enabling a genetically informed approach to cancer medicine",
        "Background":"['Background', '  Oncogenic genetic alterations drive neoplastic cell proliferation. An increasing number of potentially actionable alterations (PAAs) can be targeted by small molecules and antibodies. Since most patients (pts) do not have PAAs detectable by conventional clinical assays, NGS may identify these targets and increase treatment options. To determine the clinical impact of extensive genetic profiling, we reviewed our experience using a targeted NGS platform (FoundationOne) in advanced cancer pts.  Methods', '  We retrospectively assessed demographics, NGS results, and therapies received for pts undergoing targeted NGS (exonic sequencing of 236 genes and selective intronic sequencing from 19 genes) from April 2012 to August 2013. PAAs were defined as somatic genetic changes inferred to confer sensitivity to approved or investigational agents. Co-primary endpoints were the proportion of pts with PAAs uncovered by NGS and the proportion who received genotype-directed therapy (GDT).  Results', '  Samples from 103 pts were tested; most frequently breast carcinoma (26%), head and neck cancers (23%), and melanoma (10%). Most samples (83%) harbored 1 PAA; 6% had no detected mutations. Identified PAAs included alterations in the following pathways', ' cell cycle regulation (44%), PI3K-AKT (31%), and mitogen-activated protein kinase (19%); TP53 was the most commonly altered gene (32%). With median follow up of 4.1 months, 21% received GDT. Of these, 61% were on clinical trials and 39% received approved or off-label GDT; several heavily pre-treated pts experienced significant benefit. Rationale for not administering GDT to pts with PAAs included assignment to standard therapy during follow up (35%) and clinical deterioration (13%).Additionally, a novel BRAF fusion was identified in melanoma.  Conclusions', '  A targeted NGS panel identified PAAs in the majority of advanced cancer pts in our experience. The assay identified treatment options, facilitated enrollment in clinical trials, and identified novel PAAs. As time progresses, NGS results will be used to guide therapy in an increasing proportion of pts.']",
        "Doc_id":"ASCO_126966-144",
        "Doc_title":" Enabling a genetically informed approach to cancer medicine",
        "_version_":1606189001912352768},
      {
        "Meeting_name":" Detecting driver genes based on tumor whole-exome sequencing studies",
        "Background":"['Driver somatic mutations confer a selective growth advantage to tumors while passenger mutations do not. Genes carrying driver mutations are detected in whole-exome sequencing (WES) studies if their non-synonymous mutations are significantly more frequent than their silent mutations, adjusting for the heterogeneous mutation rates across genomic locations, subjects and mutation types. Typical tumor WES studies (100-300 tumor samples) lack statistical power, and thus can identify only small numbers of candidate driver genes and possibly miss the well-established ones. The best algorithm to detect driver genes to date is MutSigCV. For each target gene, MutSigCV identifies its bagel, a set of genes predicted to have similar background mutation rates to the target gene and use the bagels to estimate the background mutation rate. Based on the identified bagels, we developed a novel statistical method implementing a series of algorithms to improve the statistical power while maintaining the type-I error rate. First, we developed a statistical framework for testing the selective growth advantage of each mutation type and appropriately integrating evidence of growth advantage across mutation types to achieve robust power. We then extended the algorithm to consider spatial clustering information. This substantially improves the statistical power when non-silent mutations are clustered into a few short regions or nucleotides. We applied this novel method to TCGA melanoma WES including 271 tumor samples. Without modeling spatial clustering information, over 30 candidate driver genes, including BRAF, NRAS, PTEN, TP53, PPP6C and CDKN2A were detected controlling FDR=0.01. Modeling spatial information of somatic mutations detected additional rarely mutated genes, including DISP1 (P=1.310-20, involved in cellular proliferation and differentiation that leads to normal development of embryonic structures), IDH1 (P=1.010-8, previously identified in relation to gliobalstoma and acute myeloid leukemia), MAP2K1 (P=510-18, a member of the mitogen-activated protein kinases that also include BRAF, MEK and other important players in melanoma), INTS8 (P=7.710-15, an integrator of small nuclear RNA processing), and STK19 (P=1.210-10, encoding a serine/threonine kinase, previously identified in melanoma). Finally, we developed methods to simultaneously analyze multiple cancers to improve the power for genes mutated in more than one cancer type, which will be illustrated by analyzing 12 major cancers in TCGA. Our method will provide an important tool for improving driver gene mutation detection in cancer.']",
        "Doc_id":"AACR_2014-2372",
        "Doc_title":" Detecting driver genes based on tumor whole-exome sequencing studies",
        "_version_":1606188990614994944},
      {
        "Meeting_name":" Mutation detection in circulating tumor DNA in stage I vs. later stage cancer samples.",
        "Background":"['Background', ' Tumor cells release small DNA fragments into the bloodstream as circulating tumor DNA (ctDNA), a subset of cell-free DNA (cfDNA). CancerIntercept is a CLIA validated, laboratory-developed blood test that can be used by physicians as a screening tool for the detection of biomarkers associated with specific cancer types in patients without a cancer diagnosis but at high risk for developing a cancer or as a test to monitor patients who have been diagnosed with cancer. The assay detects the presence of 96 mutations in nine genes (BRAF, CTNNB1, EGFR, FOXL2, GNAS, KRAS, NRAS, PIK3CA, TP53). Since less has been published about ctDNA mutation detection in patients with early stage cancers, we sought to determine the frequency detected in these patients in comparison to those with stage III or IV tumors. Methods', ' 45 commercial plasma samples from individuals with stage I-II cancer and 36 samples from patients with stage III-IV cancer were analyzed. Cancer types included breast, colorectal, \\\\endometrial, gastric, lung, melanoma, ovarian, pancreatic, thyroid, head and neck, and prostate cancer. Clinical information such as grade, TNM, tumor size, lymph node status was available for most samples. For each sample, 1-2 ml of frozen plasma were processed, cfDNA isolated, and run on the 96 mutation panel for ctDNA enrichment followed by next-generation sequencing. Results', ' Six of the 42 stage I specimens (14%) had at least one positive mutation above limit of detection (2/6 gastric, 3/7 pancreatic, 1/8 thyroid cancer). One pancreatic cancer sample had two mutations. Notably these mutations were detected in individuals with stage IA, T1N0M0 tumors. 18 (50%) of the stage III-IV samples had mutations detected (3/9 breast, 6/9 colorectal, 3/7 lung, 1/1 endometrial, 3/7 pancreatic, 1/1 gastric, 1/1 ovarian). The mutations found in the stage I cancers include recurrent mutations in TP53, GNAS and KRAS. The later stage samples harbored mutations in all of the genes except BRAF and FOXL2, and several samples had multiple mutations and higher on average copy numbers. Conclusions', ' Overall the ctDNA mutation rate in the stage I cancers we examined was 14%, while stage III-IV samples had a higher mutation rate (50%) and higher numbers of mutations per sample.']",
        "Doc_id":"ASCO_169206-176",
        "Doc_title":" Mutation detection in circulating tumor DNA in stage I vs. later stage cancer samples.",
        "_version_":1606189036827836417},
      {
        "Meeting_name":" Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry.",
        "Background":"['Background', ' A challenge in delivering personalized cancer care to the clinic is identifying tumor genotypes that predict response to targeted therapeutics. Methods', ' In 2008, we established a Personalized Cancer Medicine Registry (PCMR) and began consenting patients for the following', ' 1) prospective genotyping of their cancer; 2) storing their tumor material for future research; and 3) permission to re-contact them if their tumor genotype fits the profile for a new therapeutic. As of the end of 2009, more than 800 patients were enrolled in the PCMR, including cases of colorectal carcinoma (CRC, n = 199), endometrioid carcinoma (EC, n = 95), thyroid carcinoma (TC, n = 276), bladder carcinoma (n = 80), and malignant melanoma (MM, n = 163 ). Tumor DNA from archival tissue was genotyped using a Sequenom MassArray system. Each sample was analyzed using a panel (320 assays) that detects known mutations in 29 genes. Clinical and genotyping data are stored in a web-interfaced, customized SQL database. Results', ' 95% of approached patients consented to registry enrollment. Archival tumor suitable for analysis was obtained in 95% of cases. Mutations in EC include PIK3CA (21%), CTNNB1 (13%), KRAS (11%), FBXW7 (5%), TP53 (5%), AKT1 (4%), FGFR2 (3%), NRAS (1%) and PDGFRA (1%); 14 cases harbor 2 or more mutations. Among cutaneous MM we found mutations in BRAF (47%; 10.8% other than V600E), NRAS (13%), CTNNB1 (3%), PIK3CA (2%), AKT1 (1%) and MEK2 (1%). In CRC we found mutations in KRAS (30%), TP53 (16%), PIK3CA (12%), NRAS / BRAF / FBXW7 (3% each), CTNNB1 (2%), and MEK1 / AKT1 / AKT2 / RET (1% each). Remarkably, 10 of 14 CRC tumors (71%) with a PIK3CA mutation also have a KRAS mutation. In TC, we found mutations of BRAF (63%), RET-PTC (7%), and PIK3CA/KRAS/NRAS/HRAS (1.5% each). Conclusions', ' Prospective tumor genotyping for PCMR patients reveals a remarkable diversity of potentially druggable mutations, knowledge of which will help in clinical trial enrollment. While rare in the examined tumors, mutations in FGFR2, MEK1/2, AKT1/2, PDGFRA and RET could be targeted as part of individualized cancer treatments. In CRC, the common overlap of PIK3CA mutations with KRAS mutations may negatively impact response to inhibitors of the PI3 kinase pathway.']",
        "Doc_id":"ASCO_43173-74",
        "Doc_title":" Mass spectroscopy-based cancer genotyping of 800 patients enrolled in a personalized cancer medicine registry.",
        "_version_":1606189038180499456},
      {
        "Meeting_name":" BRAF fusions in clinically advanced non-small cell lung cancer",
        "Background":"['Background', ' Although far less common than BRAF V600E base substitutions (subs) classically associated with melanomas and colorectal carcinomas, BRAF subs occur in 1-2% of non-small cell lung cancer (NSCLC). BRAF fusions are emerging treatment targets for Spitzoid melanomas and other solid tumors. The frequency of BRAF fusions and targeting potential in NSCLC has not been widely described. Methods', ' Hybridization capture-based comprehensive genomic profiling (CGP) was performed on 17,128 NSCLC FFPE samples sequenced to a mean coverage depth of > 550X for up to 315 cancer-related genes plus 37 introns from 19 genes frequently rearranged in cancer. Genomic alterations (GA) included short variant (SV) base subs and insertions/deletions, copy number alterations, and rearrangements/fusions. Tumor mutational burden (TMB; mut/Mb) was calculated on up to 1.1 Mb of sequenced DNA. Results', 'BRAF fusions were identified in 42/17,128 (0.2%) NSCLC profiled. Median patient age was 67 (range 44-93 yrs). Of the BRAF fusion positive NSCLC, 55% were female. Biopsies were obtained from primary lung tumor (48%) and metastatic sites (52%). The most frequent 5 partners were AGK, DOCK4, and TRIM24. Multiple novel BRAF fusions were identified. The genes most frequently co-altered with BRAF fusions were TP53(67%), CDKN2A(31%), EGFR (29%) and CDKN2B (26%). Overall TMB in the BRAFfusion positive cohort was low (median 3.8 mut/Mb), although 3/42 cases (7%) had > 20 mut/Mb. Of the BRAF fusion driven NSCLC, 10 cases (24%) featured EGFR SV alterations. Two BRAF fusion/EGFR SV cases featured primary exon 19 deletion and T790M mutation. Examples of BRAF fusion driven NSCLC responding to a combination of BRAFand MEK inhibitors (MEKi) will be presented. Conclusions', ' NSCLC BRAF fusions are a rare GA that may be associated with acquired resistance in a subset of EGFR-mutated NSCLC progressing on anti-EGFR TKI therapies. Given clinical evidence for the activity of targeted therapy approaches, molecular eligibility for clinical trials of MEKi should include these variants. The clinical evidence for responsiveness of BRAF fusion driven NSCLC provides an opportunity to personalize treatments and improve clinical outcomes for patients.']",
        "Doc_id":"ASCO_185210-199",
        "Doc_title":" BRAF fusions in clinically advanced non-small cell lung cancer",
        "_version_":1606189032873656320},
      {
        "Meeting_name":" Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing.",
        "Background":"['Background', '  Multiplex panel testing studies evaluating cancer susceptibility in breast cancer (BC) patients suggest that between 4-11% of BRCA1/2 negative individuals have a deleterious mutation in a high or moderate penetrance gene.  The range in mutation positivity is likely due to heterogeneity of the studied patient populations.   Methods', '  We performed targeted, massively parallel sequencing of 795 BRCA1/2 negative BC patients in a research laboratory and analyzed 18 cancer susceptibility genes.Three high risk groups were studied', ' multiple primary cancers (MP, n = 315), early onset breast cancer (EOBC, n = 323), and familial breast cancer (FBC, n = 415).  MP was defined as at least one BC and at least one other primary malignancy excluding non-melanoma skin cancer, EOBC was defined as BC under age 40, and FBC was defined as at least three first to third degree relatives with BC under age 75.   Results', '  Overall, 78 patients (10%) were found to have a deleterious mutation. Mutations were found most commonly in CHEK2 (n = 32, 4.0%), ATM (n = 14, 1.8%), TP53 (n = 10, 1.3%), and MSH6 (n = 4, 0.5%).  One to two patients each had deleterious mutations in BARD1, BRIP1, CDKN2A, MRE11A, MSH2, NBN, PALB2, PTEN, PMS2, and RAD50; no mutations were identified in CDH1, MLH1, or STK11.  Deleterious mutations were more common in MP patients versus FBC patients without MP (12% versus 7%, p = 0.04) but not EOBC patients without MP (10%, p = NS).  CHEK2 and MSH6 mutations were more common in MP versus non-MP patients (6% vs 3% and 1.3% vs none, respectively, p = 0.05) whereas ATM mutations were more common in non-MP patients (0.6% vs 2.5%, p = 0.05).  The most common cancers in mutation carriers were a second primary breast cancer, sarcoma, melanoma, hematological malignancies, ovarian, thyroid and uterine cancer.  There was a similar distribution of malignancies in MP mutation carriers versus non-mutation carriers.  Sequencing is ongoing for 276 additional MP patients to validate these findings.  Conclusions', '  Our results indicate that multiplex panel testing may find a higher rate of mutations in patients with MP malignancies as compared to patients with FBC alone; however, the type of second primary malignancy may not be predictive of mutation status.']",
        "Doc_id":"ASCO_149202-156",
        "Doc_title":" Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing.",
        "_version_":1606188979068076032},
      {
        "Meeting_name":" MELADIAG",
        "Background":"['Background', ' Genetics of melanoma (MM) has greatly progressed in the last decades by the discovery of mutations in BRAF, NRAS and KIT. However, there is a large genetic variability not only of a tumor to another but also depending on the stage of the disease. In order to deepen our knowledge about this and for a purpose referred to therapeutic and prognosis we studied 118 MM tumors and 73 nevi by target next generation sequencing. Methods', ' After extraction, tumor DNA of 118 tumors (44 metastatic tumors, 46 SSM, 11 ALM, 5 nodular, 2 Dubreuilh and 3 spitzoid) and 73 nevi (50 benign nevi, 18 dysplastic nevi and 5 spitzoid nevi) were sequenced using a panel of 15 genes (ALK, BRAF, CDKN2A, CTNNB1, GNA11, GNAQ, KIT, NOTCH1, NOTCH2, NRAS, RAC1, RAF1, SF3B1, TERT and TP53) on a new generation sequencer (PGM Ion Torrent) using chips 318 with a depth > 51000x . The analysis of the variants was made by dedicated software (Ion Reporter, wAnnovar) and we selected only those which had a sufficient quality score. Results', ' The results of the sequencing showed the presence of very large number of mutations. In the begnin nevi, excepting BRAF mutations (V600E and V600K, present in 86%) there were no other mutations. At the opposite, the percentage of mutations in many other genes (ALK, KIT,CDKN2A,TP53...) in MM tumors range from 55% (Breslow < 1mm) to 90% in metastatic tumors. More than 80% of mutations were transitions C > T reflecting the UV-induced mutagenesis. Interestingly, in 33% of atypical and Spitz nevi, we also found at least one mutation in one of these genes (40% of these mutations were reported in Cosmic databases). Comparison of the proportion of somatic mutations between the different types of nevi, tumors with low thickness and metastatic tumors clearly showed an accumulation of somatic mutations during tumor development. Conclusions', ' This chip dedicated to MM is interesting', ' high sensitivity, allowing a better tumor classification and rapid identification of therapeutic targets. In addition, it could help for MM diagnosis in case of pigmented lesions with atypical component or uncertain diagnosis. In a second step, this panel of markers will be used to detect circulating tumor DNA in plasma of patients and to correlate their presence with melanoma prognosis.']",
        "Doc_id":"ASCO_167776-176",
        "Doc_title":" MELADIAG",
        "_version_":1606188995637673984},
      {
        "Meeting_name":" Identification of germline variants in cancer susceptibility genes in patients with multiple primary cancers",
        "Background":"['The occurrence of multiple primary (MP) cancers in a patient suggests a genetic predisposition to tumor formation. Multiplex panel testing may be an efficient way of evaluating MP patients for the presence of germline mutations in cancer susceptibility genes. However the spectrum of mutations in many cancer susceptibility genes in the MP patient population is largely unknown. We performed massively parallel sequencing using targeted capture of 15 genes with well-established risks of breast and/or other cancers, specifically TP53, CDH1, PTEN, STK11, ATM, CHEK2, MRE11A, NBN, RAD50, PALB2, MLH1, MSH2, MSH6, PMS2, and MUTYH. Our patient cohort consisted of 221 BRCA1/2 negative patients diagnosed with breast cancer and at least one other primary cancer, excluding non-melanoma skin cancer. Patients diagnosed with contralateral breast cancer were included. Thirty patients (14%) were found to have at least one deleterious variant in these 15 genes. Deleterious variants were found in CHEK2 (16 patients, 7.2%), TP53 (4, 1.8%), MSH6 (3, 1.4%), ATM (2, 0.9%) and one patient each had deleterious variants in CDKN2A, PTEN, PMS2, PALB2, BRIP1 and NBN. In addition, six patients (2.7%) were found to be heterozygous carriers of a MUTYH mutation. In comparison, deleterious variants were identified in 9% of 341 patients with breast cancer only, indicating a small but nonsignificant increase in the rate of deleterious variants in MP patients. The rate of MUTYH heterozygous mutations was also non-significantly different in patients with breast cancer only (1.2%). There was a significant increase in the rate of CHEK2 and MSH6 mutations in the MP versus breast-only patients (7.2% vs 3.5%, p = 0.04 for CHEK2 and 1.4% vs 0%, p = 0.05 for MSH6). As a corollary study, a subset of MP patients (n = 165) were assayed on a panel including TET2. Deleterious TET2 mutations were identified in 2 of 165 patients (1.2%) at allele frequencies of 0.17 and 0.36. These patients blood samples were ascertained at ages 77 and 72, respectively. These preliminary data show that in our cohort of patients with multiple primary cancers, over 16% of patients were found to have deleterious variants in 15 cancer susceptibility genes. In addition, approximately 1% of MP patients have deleterious variants in TET2 that may be due to age-related clonal hematopoiesis, although it is unknown if these mutations are related to the development of the tumors in these individuals. Further analysis of variants in less well-characterized cancer susceptibility genes and unclassified variants is ongoing. Discovery of clinically relevant mutations can potentially guide future treatment practices for those with similar diagnoses to our patients.']",
        "Doc_id":"AACR_2015-4663",
        "Doc_title":" Identification of germline variants in cancer susceptibility genes in patients with multiple primary cancers",
        "_version_":1606188978688491520},
      {
        "Meeting_name":" Benchmarking algorithms for mutation impact prediction using functionally validated missense mutations",
        "Background":"['Background', ' Massively parallel sequencing studies have demonstrated that there are few highly recurrently mutated genes in tumors and that there are vast numbers of mutations found in a minority of cancers from a given anatomical site. Numerous bioinformatics tools to predict the effect of a given amino acid substitution on protein function are available, and there is no consensus as to which prediction algorithms are the most appropriate for the identification of driver mutations. Here we sought to compare the performance, as standalone or in combination, of nine algorithms predictive of the impact of a mutation on protein function, when challenged against mutations whose pathogenic role is supported or refuted by in vitro or in vivo experiments, or have been shown to be pathogenic in the context of familial cancer syndromes.Methods', ' We mined the literature and databases and compiled known mutations for six oncogenes (BRAF, KIT, PIK3CA, KRAS, EGFR, ERRB2) and three tumor suppressors (TP53, BRCA1, BRCA2). We applied Boolean logic to identify experimental and clinical evidence of functional effects for each mutation. A total of 3072 missense mutations were subjected to analysis using nine mutation impact predictor algorithms, namely CHASM lung/breast/melanoma, FATHMM cancer/missense, Mutation Assessor, MutationTaster, PolyPhen-2, Condel, Provean, VEST and SIFT. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated and the agreement between predictors evaluated. Furthermore, predictions made by combinations of algorithms were assessed.Results', \" The PPV of all predictors was relatively high (median 0.941, range 0.909-0.989). Their sensitivity, specificity and NPV, however, varied widely. The median sensitivity was 0.854 (range 0.632-0.987), with the best performers being FATHMM cancer, CHASM lung and melanoma. The median specificity was 0.667 (range 0.482-0.939), with CHASM breast performing best. Inter-predictor agreement was only fair-to-moderate for most pair-wise comparisons (kappa scores ranging from 0.187 to 0.826). Finally, 358/4653 combinations performed better than each of the algorithms tested alone; 163/358 displayed higher NPVs and 131/358 improved sensitivity than the highest single algorithm's NPV and sensitivity, i.e. FATHMM cancer. The combination CHASM/FATHMM cancer/MutationTaster showed excellent performance, with sensitivity, specificity, PPV and NPV of 0.988, 0.824, 0.974 and 0.913, respectively.Conclusions\", ' Our results revealed discrepancies in performance of mutation impact predictors. No algorithm, on its own, was able to distinguish accurately driver from passenger events. Combining algorithms that provide orthogonal information likely results in substantial improvements in the functional predictions.']",
        "Doc_id":"AACR_2014-4258",
        "Doc_title":" Benchmarking algorithms for mutation impact prediction using functionally validated missense mutations",
        "_version_":1606189027762896896},
      {
        "Meeting_name":" Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.",
        "Background":"['Background', ' MM is a highly targetable malignancy, with both kinase inhibitors and immunotherapies providing meaningful survival benefit. Different subtypes of mm harbor distinct GA that suggest targeted and immunotherapy options. Methods', ' Comprehensive genomic profiling was performed in 2,197 MMs for up to 315 cancer-related genes plus introns from 28 genes commonly rearranged in cancer on hybrid-capture, adaptor ligation-based libraries (mean coverage depth > 600X). TMB was calculated from 1.11 Mb sequenced DNA. We assessed base substitutions, insertions and deletions (short variants; SV), rearrangements, and copy number changes. Results', ' We assessed 6 subtypes', ' routine cutaneous (CT; 90%), desmoplastic (DM', ' 1%), acral lentiginous (AL; 1%), Spitzoid (SP; 1%), mucosal (MC; 2%) and ocular (OC; 5%). Each group harbored characteristic genomic signatures (Table). BRAFwas mutatedin 38% of CT of which 92% were SV GA and 8% were amplifications, fusions or cases with > 1 BRAF GA. High TMB in CT and DM is highly prevalent (42% and 83% with > 20 mut/Mb). BRAFGA were less common in AL (18%), MC (15%), and OC (2%). SP GA were dominated by fusions in BRAF (60%) and other kinases. KIT GA were prominent in MC and AL. TMB for MC and OC mm were very low. Key findings include novel drivers of BRAF inhibitor resistance including BRAFinternal rearrangements and kinase domain duplications. Conclusions', ' In the largest cohort of mm with NGS to date, genomic profiles and TMB differ across mm subtypes. Highly prevalent BRAF GA (including in the SP variant) and high TMB in CT and DM mm permit effective use of targeted and immunotherapies. Although MC and OC have lower BRAF GA frequency and lower TMB, targetable GA can be present. Novel BRAF inhibitor resistance mechanisms were observed. CutaneousDesmoplasticAcral-LentiginousSpitzoidMucosalOcularNumber199112222244105Significant driver GABRAF(38%)BRAF (0%)BRAF(18%)Fusions in', 'BRAF(15%)BRAF (2%)NF1(21%)TP53 (75%)NF1(18%)BRAF(60%)NF1(32%)NF1 (2%)PTEN(12%)NF1 (50%)PTEN(18%)ROS1(3%)KIT(25%)(GA in BAP1, GNAQ, GNA11 or MYC in 100%)KIT (5%)KIT (18%)RET(3%)PTEN (13%)NTRK1(1%)ALK (1%)TMB > 10 mut/Mb61%92%NANA3%3%High TMB > 20 mut/Mb42%83%NANA01%']",
        "Doc_id":"ASCO_187678-199",
        "Doc_title":" Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.",
        "_version_":1606189032519237632},
      {
        "Meeting_name":" Novel, ultra deep next-generation sequencing of plasma cell-free DNA from patients with advanced cancers",
        "Background":"['Background', ' Plasma cell-free (cf) DNA from cancer patients offers an easily obtainable and repeatedly applicable source of DNA for mutation analysis, which provides attractive alternative to tumor tissue testing. Novel ultrasensitive multiplex technologies using small amounts of DNA are needed for further implementation of plasma cfDNA testing in personalized therapy.Methods', ' We have developed an ultra-deep next-generation sequencing method for somatic BRAF mutation detection in 5 ng of cfDNA with high sensitivity and specificity, which was expanded to include 30 (full exon tiling', ' ERBB2, TP53, FGFR1, PTEN, MET, KRAS, ALK, CTNNB1, KIT, NRAS, BRAF, PIK3CA, EGFR, MAP2K1, PIK3R1, DDR2, NF1, MITF, AKT3, PHLPP1, HGF, HOXD8, MEK2, hotspot containing exons', ' AKT1, HRAS, GNA11, GNAQ, RAC1; copy number variations', ' ERBB2, FGFR1, MET, BRAF, EGFR, MITF, HGF, HOXD8; gene fusions', ' RET1, ROS, and ALK) and then 58 common cancer related genes (previous panel + APC, AR, FGFR2, FGFR3, FGFR-4, SMO, FBXW7, NOTCH1, CDKN2B, IDH1, IDH2, GNAS, KDR, STK11, ESR1, VHL, ATM, CDH1, TRKA, TRKB, TRKC, TSC1, TSC2, Fltr3, FOXL2, CDKN2A, PDGFRA, IGF1R). Each cfDNA fragment was uniquely barcoded and amplified prior to Illumina target enrichment workflow, followed by ultra-deep sequencing (>10,000X). Proprietary data processing and analysis tools were developed to enable sensitive detection of rare mutant molecules over high wild-type background (detection of 1 in 1,000 - 10,000 molecules). Results were compared to mutation analysis of archival primary or metastatic tumor tissue obtained at different points of clinical care from a CLIA-certified laboratory.Results', ' Initially, cfDNA was extracted from plasma samples of 24 patients with advanced cancers (melanoma, n = 9; colorectal, n = 5; non-small cell lung, n = 2; papillary thyroid, n = 2; other cancers, n = 6) and 5ng were used for BRAF mutation analysis. BRAF mutations were detected in 71% (17/24) of plasma samples and in 88% (21/24) of archival tumor samples, resulting in concordance in 87% (20/24) of cases. Subsequently, we extracted plasma samples from additional 13 patients with advanced cancers (colorectal, n = 4; melanoma, n = 3; other cancers, n = 6) and tested 14-30ng of cfDNA for the presence of alterations in 30 to 58 cancer related genes. Both ultra-deep sequencing of plasma cfDNA and standard tissue sequencing detected median of 2 alterations per patient and dominant oncogenic alterations previously detected in the tumor tissue were also found in plasma cfDNA. Additional 80 samples are being analyzed and results will be presented at the meeting.Conclusions', ' Detecting common oncogenic alterations using ultra-deep sequencing of plasma cfDNA is feasible with an acceptable level of concordance with testing of tumor tissue and should be further investigated for testing in patients with advanced cancer.']",
        "Doc_id":"AACR_2015-2414",
        "Doc_title":" Novel, ultra deep next-generation sequencing of plasma cell-free DNA from patients with advanced cancers",
        "_version_":1606189008548790272},
      {
        "Meeting_name":" Germline genetic testing in unselected pancreatic ductal adenocarcinoma (PDAC) patients.",
        "Background":"['Background', ' The aim of this study is to assess the prevalence of known heritable germline mutations in unselected PDAC patients and to determine how well current guidelines for genetic testing identify mutation carriers. Methods', ' Consecutive, unselected patients with recently diagnosed PDAC from three centers were enrolled from May to December 2016 in an ongoing prospective study. A three-generation pedigree was obtained. Germline mutations in 12 genes associated with PDAC risk (APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, PALB2, PMS2, STK11, TP53) and in 19 genes related to other cancer risks were screened for by NGS. American College of Gastroenterology and NCCN criteria for genetic testing for BRCA1/2, Lynch syndrome, and Familial Pancreatic Cancer (FPC) were assessed. Results', ' Among 183 patients, 46% are female, 79% are Caucasian and 10% are Ashkenazi Jewish, with median (IQR) age 68 (62,75) years at diagnosis. 41% of patients met 1 criteria for genetic testing (35.5% BRCA1/2, 2.7% Lynch, 9.3% FPC). Twenty patients (11%) were found to have a total of 21 pathogenic mutations (table). Mutation status was not associated with age at diagnosis, sex, or personal history of cancer (all p > 0.05). Six mutation carriers (30% of positives) did not meet current criteria for genetic testing. Conclusions', ' Preliminary results show that 6.6% of unselected PDAC patients carry a germline mutation in a gene known to increase PDAC risk and 4.3% have a mutation in genes not previously linked to PDAC. Existing testing criteria did not identify 30% of carriers. Continued refinement of guidelines is necessary to align genetic testing with inherited PDAC risk. Clinical trial information', ' NCT02790944PatientGeneMutationTesting Criteria MetBRCA1/2LynchFPC1ATMc.1027_1030delGAAAYNN2ATMc.1564_1565delGAYNN3ATMc.3245_3247delATCinsTGATNNN4ATMc.5932G > TNNN5ATMc.6027C > GNNYRAD50c.1052-2A > C6ATMc.7630-2A > CNNY7BRCA1c.68_69delAGYNN8BRCA1c.181T > GYNN9BRCA1c.5266dupCYNN10BRCA2c.1237delCYNN11*CDKN2Ac.-34G > TNNN12CHEK2c.470T > CYNN13CHEK2c.470T > CNNN14CHEK2c.470T > CYNY15CHEK2c.470T > CYYN16CHEK2c.1116dupCYNN17CHEK2c.1283C > TYNY18CHEK2EX8_9delNNN19MSH6c.2230dupGNNN20NF1c.663G > ANNY*No personal or family history of melanoma or other PDAC']",
        "Doc_id":"ASCO_184479-199",
        "Doc_title":" Germline genetic testing in unselected pancreatic ductal adenocarcinoma (PDAC) patients.",
        "_version_":1606189005594951680},
      {
        "Meeting_name":" Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma",
        "Background":"['Background', ' Predictive biomarkers for response and resistance to immune checkpoint blockade targeting programmed death 1 (PD-1) are incompletely characterized, and the utility of anti-PD-1 therapy for uterine leiomyosarcoma (ULMS) is unknown. Methods', ' A 49 yo woman with ULMS developed rapidly progressive metastatic disease 4 months after R1-resection of the primary tumor and was enrolled on a phase 1b study of pembrolizumab (10 mg/kg every 2 wks) (KEYNOTE-028). Tumor regression at multiple metastatic sites occurred within 2 months. A single pre-existing metastasis increased in size and was resected at 9 months. IHC, whole exome/transcriptome sequencing, and neoantigen analysis was performed on primary pretreatment (preRx) and treatment-resistant tumors (postRx). Results', ' Responsive tumor sites revealed complete pathologic response at time of surgery. Progressive tumor demonstrated viable ULMS. IHC showed tumor cells negative for PD-L1 and positive for PD-L2 both preRx and postRx. Degree of PD-1+ lymphocyte infiltration decreased significantly postRx compared to preRx. PreRx harbored exomic focal MYC amplification, TP53 nonsense mutation, and heterozygous PTEN deletion. PostRx maintained these genomic alterations and acquired a loss-of-function mutation in PTEN that resulted in biallelic PTEN inactivation. PreRx tumor expressed tumor-specific neoantigens (TSNs) that were immunogenic to patient-derived peripheral blood mononuclear cells; expression of TSNs decreased postRx. Conclusions', ' This patient exhibited complete pathologic response to pembrolizumab at all but one metastatic ULMS site. Genomic analysis of the resistant tumor revealed acquired bialllelic PTEN loss - recently implicated in resistance to PD-1 inhibition in melanoma and glioblastoma  reduced infiltration of PD-1+ lymphocytes, and diminished expression of neoantigens. To our knowledge, this is the first report of exceptional response to PD-1 inhibition in ULMS, and highlights biallelic PTEN loss and neoantigen downregulation as potential mechanisms of acquired resistance to immune checkpoint blockade across cancer types.']",
        "Doc_id":"ASCO_166429-176",
        "Doc_title":" Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma",
        "_version_":1606189008174448640},
      {
        "Meeting_name":" Characterization of cell-free circulating tumor DNA in patients with brain metastases.",
        "Background":"['Background', ' Brain metastases are the most common malignant brain tumor and a significant cause of morbidity and mortality. As patients live longer from more effective systemic therapies, they are at increased risk of developing brain metastases. Genetic profiling of tumor tissue allows for targeted therapy, though biopsy of brain metastases is not always feasible. Cell-free circulating tumor DNA (ctDNA) testing carries diagnostic potential for targeted therapy without the need for repeat biopsies, and the ability to rapidly respond to changes in the molecular profile. Methods', ' 37 patients with brain metastases (15 lung, 12 breast, 5 ovarian, 3 renal, 2 melanoma) were tested prospectively with the Guardant360 ctDNA panel at a CLIA-certified, CAP-accredited clinical laboratory. Samples were analyzed for amplifications in 18 genes, single nucleotide variants in 68 genes, and select fusions, rearrangements and indels. Results', ' 29/37 (78.4%) patients tested harbored at least one detectable genomic alteration. The median number of alterations was 3 (range, 1-12). The most frequently detected alterations were in EGFR (19), TP53 (18), APC (6), NF1 (6), PIK3CA(6). The median ctDNA concentration was 0.50% (range, 0.10-43.80%). 11/37 patients had a subsequent test. 4/11 patients were tested within 50 days of initial testing; the median number of new alterations detected was 0.5 (range, 0-1). 7/11 patients were tested greater than 50 days of initial testing; the median number of new alterations detected was 2 (range, 0-4). Conclusions', ' CtDNA testing was able to detect alterations in a majority of patients with brain metastases. An increasing number of alterations were observed with time, suggesting the utility of ctDNA analysis in monitoring changes in tumor biology, response to therapy, and the ability to refine treatment plans with changes in the molecular profile.']",
        "Doc_id":"ASCO_171553-176",
        "Doc_title":" Characterization of cell-free circulating tumor DNA in patients with brain metastases.",
        "_version_":1606189026680766464},
      {
        "Meeting_name":" Detecting low abundant mutations in circulating cell free DNA and FFPE samples",
        "Background":"['Detection of low abundant alterations in oncogenes from circulating cell free DNA (cfDNA) samples or formaldehyde fixed-paraffin embedded samples (FFPE) has been a challenge for the community. Additionally, cfDNA and FFPE samples are typically limited in the amount of material that can be obtained, and often the FFPE samples are highly degraded, compounding the ability to sequence them and to perform accurate variant calling. To overcome these challenges, we have developed a single tube, multiplexed amplicon sequencing technology that employ hundreds of primer pairs for amplification of targeted loci, producing ready-to-run libraries for Illumina sequencing platforms. The resulting amplicons are less than 150 bp in length, enabling amplification and sensitive detection of mutations from cfDNA-sized DNA fragments or highly damaged DNA. A 200+ amplicon panel across 55 genes was developed to target known clinically relevant oncological mutations. The panel design encompasses single exons (e.g. BRAF) as well as comprehensive exon coverage of entire genes (e.g. TP53).DNA was extracted from FFPE, and cfDNA was extracted from fresh plasma. DNA was quantified by qPCR using 2 primer pairs targeting ALU repeat regions. 10ng of DNA input was used to perform the multiplexed PCR. Libraries were quantified by qPCR and sequenced with MiSEQ V2 reagents, paired end reads. Alignment was performed using Burrows-wheeler Aligner (BWA) and variant calling was performed with at least two validated publicly available tools and confirmed manually by IGV. A variety of tools were used to validate allele technology was used to validate the sequencing data.We interrogated 80 FFPE samples using our amplicon technology.The percent of on-target bases was over 95% and the coverage uniformity was over 98%, where uniformity is the percent based covered over 20% of the mean coverage. Out of the 40 colorectal cancer samples tested, 17 showed mutations in KRAS. Out of the 20 melanoma samples (Cure line) also analyzed, 9 were positive for BRAF V600E. The presence of those mutations was confirmed using myTprimerTM KRAS and BRAF qPCR assay. The limit of detection of the assay was set at 3% due to the inherent noise caused by the damage from the FFPE samples. For cell lines with known mutations, the sensitivity was 0.5%. No false positive or false negative were reported. 20 FFPE samples from different cancer types were also assessed. Mutations were identified in ERBB2 (cervical cancer), ALK (lung cancer) and TP53 (colon cancer) genes, as well as MET amplification (lung cancer).Cell free DNA provides a non-invasive tool to monitor cancer progression and treatment efficacy. Tumor DNA, matching blood DNA and cfDNA from 10 cancer patients will be subjected to our multiplex PCR oncology panel. Data of this study will be presented.Our results show that this unique multiplex PCR panel is an excellent tool to assess multiple oncogenes in limiting clinical samples, enabling high throughput, cost effective NGS analysis.']",
        "Doc_id":"AACR_2015-4902",
        "Doc_title":" Detecting low abundant mutations in circulating cell free DNA and FFPE samples",
        "_version_":1606188971681906688},
      {
        "Meeting_name":" Features of familiality in a cohort of patients (pts) with sarcoma.",
        "Background":"['Background', '    Sarcomas occur in a number of cancer predisposition syndromes, yet genetic evaluation is rarely recommended for sarcoma pts. We broadly reviewed the family cancer histories of unselected pts in a tertiary center sarcoma clinic to explore the potential relevance of genetic assessment.  Methods', '    Between 2005 and 2008, 397 pts (median age 52 years) with documented sarcoma who consented to research use of medical records and tissues also completed a family history questionnaire. Patient and family histories were reviewed for features suggesting hereditary risk (e.g. early age at diagnosis or familial clustering of certain associated diagnoses).   Results', '    A family history of malignancy was noted in 301 of 397 pts (76%). Seventy-six pts (19%) were diagnosed with 99 additional malignancies, most frequently breast cancer (n=23), prostate cancer (12), melanoma (12), thyroid cancer (6) or a second sarcoma (10). Sarcoma was diagnosed prior to or synchronously (within 6 months) with another malignancy in 20 pts and metachronously in 56 pts. In 18 pts, sarcoma arose within a prior radiation field. Thirty-seven pts (9%) had a sarcoma subtype associated with a recognized syndrome', ' desmoid fibromatosis (n=16), malignant peripheral nerve sheath tumor (11), PEComa/angiomyolipoma (6), retinoblastoma (3), and GIST with paraganglioma (1). Based on additional features, the associated syndromes were confirmed in 6 of them (1.5% of the cohort)', ' familial adenomatous polyposis (n=1), neurofibromatosis type 1 (2), familial retinoblastoma (2), and Carney-Stratakis dyad (1). Thirty-three pts (8% of the cohort, or 16% of pts age <50) fulfilled TP53 testing criteria (Chompret, Birch or classical Li-Fraumeni Syndrome [LFS] criteria). Another 147 pts (37% of the entire cohort) did not fulfill LFS testing criteria, but were diagnosed with sarcoma before age 50 and had at least one first or second degree relative with a diagnosis of malignancy before age 50.  Conclusions', '     Sarcomas are rare and diverse cancers.  Given the potential association with cancer predisposition syndromes, genetic evaluation should be strongly considered in sarcoma pts based on age at diagnosis, histology, and family cancer history.']",
        "Doc_id":"ASCO_97994-114",
        "Doc_title":" Features of familiality in a cohort of patients (pts) with sarcoma.",
        "_version_":1606188972445270016},
      {
        "Meeting_name":" Emerging findings in the Cancer Research UK stratified medicine program.",
        "Background":"['Background', '  Molecular analysis of tumours may be used to identify those predicted to benefit from novel targeted therapies. The Cancer Research UK programme is piloting plans to apply such testing broadly across the UK healthcare system, linking molecular phenotype to clinical outcomes.   Methods', '  The Stratified Medicine Programme (SMP) aims to develop a model for high quality, large-scale molecular characterization of cancer specimens through an initiative developed in partnership with AstraZeneca, Pfizer, the UK Department of Health and academic researchers. Phase One of the SMP is a two year feasibility study. It aims to demonstrate the submission of consented blood samples and sections of surplus diagnostic formalin-fixed paraffin-embedded tumour tissue from 9,000 patients at centres across the UK to one of three technology hubs for mutation testing of genes of potential clinical interest (KRAS, BRAF, NRAS, PIK3CA, TP53, PTEN, TMPRSS2-ERG, EGFR, EML4-ALK and KIT) in six selected tumour types. The tests are technically validated and will be completed in clinically relevant timescales.  Data including pathological and treatment information and clinical outcome is also collected for the recruited patients, linked to the genetic data and stored in a central data repository hosted within the National Cancer Registration Service.  The study opened in September 2011 at 7 sites across the UK and by the end of 2011, 760 patientswith breast, lung, prostate, colorectal, ovarian cancer or metastatic malignant melanoma had consented to participate.  142 sets of molecular results had been returned to clinical teams. Updated figures will be presented at the meeting, by which time the programme is projected to have accrued 4000 subjects.  By 2013, we hope to have developed a scalable model for routine, high quality, prospective molecular characterisation of tumours for NHS cancer patients, with consent for the collection, storage and research use of population-scale genetic and clinical outcome data. We will report the emerging results from the Stratified Medicines Programme and early insights into implications for wider implementation across the UK healthcare system.']",
        "Doc_id":"ASCO_99103-114",
        "Doc_title":" Emerging findings in the Cancer Research UK stratified medicine program.",
        "_version_":1606188992689078272},
      {
        "Meeting_name":" Oncologic outcomes of advanced gynecologic malignancies managed with the aid of comprehensive genomic profiling (CGP) in a rural community setting.",
        "Background":"['Background', ' Managing advanced gynecologic malignancies represents a challenge. Chemotherapies for recurrent disease have limited efficacy, as they are selectied ignoring the role that tumor heterogeneity plays in achieving a lasting response. We utilized multiplatform comprehensive genomic profiling (CGP) to identify relevant genomic alterations (CRGA) to be targeted in combination with standard chemotherapies. Methods', ' CGP were performed from DNA extracted from formalin-fixed paraffin-embedded tissue of advanced gynecologic cancers. All classes of GA were evaluated, and clinically relevant genomic alterations (CRGA) were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials. Therapy recommendations combining standard of care single agent chemotherapies and agents targeting CRGA were made. Results', ' A total of 66 patients with advanced, recurrent or progressive gynecologic malignancies have been enrolled in the study. Twenty-five subjects (38%) with a median age of 62 (32  88) are evaluable at this time. There were 17 (68%) ovarian carcinomas, 4 (16%) endometrial carcinomas, 2 (8%) uterine sarcomas, and 1 (4%) case each of vaginal melanoma and a tumor of unknown gynecologic primary. Sixteen percent were stage I (16%), 1 (4%) stage II, 17 (68%) stage III and 3 (12%) stage IV. CGP revealed that 80% of cases exhibit at least 1 CRGA, for an average of 1.83 CRGA per case. All subjects tumors demonstrated at least one GA, for a total of 107 GA and an average of 4.56 GA/case. The most frequently detected GA was in TP53 (37%), and the most common CRGA were PTEN, MYC, PIK3CA, PIK3R1, NF1, KRAS,BRCA2 and BRAF. Overall response rate (ORR) was 68%, for an overall clinical benefit of 76% (CR 32% + PR 36% + 8% SD). Progressive disease was seen in 6/25 (24%) subjects. Conclusions', ' Management of advanced gynecologic malignancies targeting CRGA in combination with standard chemotherapy is feasible and results in superior therapeutic outcomes compared to historical controls. Further applications of CGP for precision oncology in gynecologic malignancies appear to be warranted and deserve further evaluation.']",
        "Doc_id":"ASCO_171739-176",
        "Doc_title":" Oncologic outcomes of advanced gynecologic malignancies managed with the aid of comprehensive genomic profiling (CGP) in a rural community setting.",
        "_version_":1606188996241653760},
      {
        "Meeting_name":" Frequency of clinically relevant genomic alterations using comprehensive genomic profiling (CGP) for the management of advanced gynecologic malignancies in a community setting.",
        "Background":"['Background', '  The management challenges of advanced gynecologic malignant neoplasms are often intensified in a community setting. We utilized comprehensive genomic profiling (CGP) of advanced gynecologic malignancies to identify routes of possible benefit from targeted therapy.  Methods', ' DNA was extracted from 40 microns of FFPE sections of advanced gynecologic malignancies. CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of > 500x for 3,769 exons of 236 cancer-related genes plus 47 introns from 19 genes frequently rearranged in cancer. All classes of genomic alterations (GA) were evaluated, and clinically relevant genomic alterations (CRGA) were defined as GA linked to drugs on the market or under evaluation in mechanism driven clinical trials.  Results', '  The 30 female patients had a median age of 62 years (range 32-88). There were 16 (56%) ovarian carcinoma, 9 (30%) endometrial carcinoma, and 1 (3.3%) case each of uterine sarcoma, uterine carcinosarcoma, leiomyosarcoma, vaginal melanoma, and peritoneal carcinoma. CGP revealed 80.00% (24/30) of cases harbored at least 1 CRGA, for  an average of 1.83 CRGA per case, and 100% of cases harbored at least one GA, for a total of 137 GA, for an average of 4.56 GA/case. The most frequently detected GA was in TP53 (52%), and the most common CRGA were in PTEN 36% (11/30), PIK3R1 28%(9/30), CDKN2A 12%(4/30), KRAS 12% (4/30) and PIK3CA 12% (4/30), respectively. There were 8 evaluable ovarian carcinoma patients that received therapy based on assay results, and 3/8 cases had complete responses and another 4/8 had partial responses with median duration of response of 31 weeks (range 2-43 weeks) and ongoing. The remaining evaluable patient had PD as a result of noncompliance.  Conclusions', '  In this group of patients with advanced gynecologic malignancies, CGP uncovered a high frequency of CRGA that lead to preliminary successes in multiple ovarian carcinoma patients. Further application of CGP in gynecologic cancers as a route to precision treatment for these patients appears warranted.']",
        "Doc_id":"ASCO_150967-156",
        "Doc_title":" Frequency of clinically relevant genomic alterations using comprehensive genomic profiling (CGP) for the management of advanced gynecologic malignancies in a community setting.",
        "_version_":1606188998370263041},
      {
        "Meeting_name":" The landscape for genetic eligibility to basket clinical trials.",
        "Background":"['Background', '  There is a movement toward basket trials, where eligibility is based on molecular aberrations rather than anatomical origin of a cancer.  There is a paucity of information on how many cancer patients (pts) meet eligibility for basket trials. This study assessed the genetic eligibility of cancer pts seen at a large cancer center for the currently open basket trials.  Methods', '  Moffitts Clinical Genomic Action Committee (CGAC) database was used to assess 236 pts across 30 cancer types with targeted deep sequencing as part of clinical care between 1/1/2013 and 12/31/2014. Pts were screened for basic histologic and genetic eligibility on all basket trials open in North America in January, 2015 (Novartis Signature, NCI-MATCH, NCI-M-PACT). The trials included 23 different arms utilizing different agents based on 44 different molecular alterations; 11 of these alterations allowed eligibility into multiple trials.  Results', '  Among the 236 evaluable pts, 83.5% met genetic eligibility for at least 1 of the arms examined with an average of 2.89 eligible arms per patient and a range of 0 to 15. The percentage of histologically eligible pts meeting genetic eligibility ranged from 0% (non-melanoma or colorectal BRAF V600 mutated solid or hematologic malignancy) to 50.0% (PARP1/2 or TP53 mutated solid tumor) across all treatment arms. Of 188 pts with solid malignancies, 93.6% met genetic eligibility for at least 1 of the trials vs. 45.8% of 48 pts with hematologic malignancies.  Conclusions', '  The vast majority of pts within a clinical genetic database who received somatic tumor sequencing met genetic eligibility for at least one aberration-specific clinical trial; however 16.5% of pts overall and the majority of those with hematologic malignancies remained without basket trial options. These results highlight opportunities for enrollment in clinical trials given access to both tumor sequencing and next-generation clinical trials. All Pts (n = 236)Solid Malignancies (n = 188)Heme Malignancies (n=48)Any Trial197 (83.5%)176 (93.6%)22 (43.8%)SIGNATURE160 (67.8%)139 (73.9%)22 (43.8%)NCI-MATCH22 (41.9%)97 (51.6%)Only lymphomaseligible (n = 6) 2 (33.3%)NCI-M-PACT156 (66.1%)156 (83.0%)n/a']",
        "Doc_id":"ASCO_148188-156",
        "Doc_title":" The landscape for genetic eligibility to basket clinical trials.",
        "_version_":1606189006560690176},
      {
        "Meeting_name":" A look back",
        "Background":"['Background', '   Molecular characterization of the genomic mutations underlining cancer continues to advance. At our institution we initiated a tumor genotyping program as part of routine care, screening both hematologic and solid tumors for a wide spectrum of mutations.  Herein, we describe our initial experience.     Methods', '   Upon clinician request, patient samples were analyzed using one of two NGS panels.  DNA was extracted from either fresh tissue or from Formalin Fixed- Paraffin embedded tissue and target genes were enriched using the TruSeq Amplicon Cancer Panel (47 genes) or a TruSeq Custom Amplicon panel (33 genes) with subsequence sequencing on the Miseq.  With slight alterations to the standard protocol, as low as 5 ng total input DNA was used to produce libraries with a mean depth of coverage over 2,000x.  Using custom analysis pipelines, variants were detected to an allele frequency of 5% and indel size up to 90 basepairs.  Results were returned with an average turnaround time of 7-10 days.    Results', '   Initial launch was focused on four major indications, acute myelogenous leukemia (AML), melanoma, brain and lung tumors.  During the first year of testing, over 1,000 samples were received, with 15% being cancelled for sample adequacy or appropriateness.  Of the remaining 900 samples analyzed, over 71% were found to be abnormal with at least one disease associated mutation detected; 93 of which contained only TP53 mutations.  14% of cases were found to be mutation negative, 6% contained only unclear variants and 6% contained DNA that was  insufficient for analysis.  Over 1,100 unique variants were detected across the two panels, with each abnormal case containing on average, 1.6 disease associated mutations and 0.6 variants of uncertain significance.   Conclusions', '   Multi-gene testing has shown rapid and widespread adoption across our institution.  The advance of this technology has challenged the standards of current practice and demonstrated that actionable mutations exist outside the genes currently considered as standard of care. The platform is now being extended to include actionable alleles in noncancer disease areas in our health care system.']",
        "Doc_id":"ASCO_135299-144",
        "Doc_title":" A look back",
        "_version_":1606189028404625408},
      {
        "Meeting_name":" Comparison of tissue DNA to circulating tumor DNA in patients with brain metastases.",
        "Background":"['Background', ' Brain metastases are often a late complication of cancer, not easily amenable to biopsy, and may contain additional molecular alterations not found in the original tumor. We sought to analyze the concordance between tissue DNA and cell-free circulating tumor DNA (ctDNA) in patients who developed brain metastases, and determine how the ctDNA profile changed with time. Methods', ' We retrospectively analyzed 31 patients with brain metastases who underwent next-generation sequencing (NGS) from both ctDNA and tumor tissue DNA. Breast, lung, ovarian, renal, melanoma, and colon primaries were included (42, 32, 13, 7, 3, and 3%, respectively). Tissue DNA was from primary tumor, systemic metastasis or brain (39, 39, and 7%, respectively). A median number of five alterations was found in each tissue group. Alterations in ctDNA were compared to tumor DNA and analyzed for relative frequencies, concordance, and novel alterations. Overall survival (OS) and time between DNA sample collections was analyzed. Results', ' All 31 patients had detectable mutations in tumor tissue. 25 patients (80.6%) had detectable ctDNA alterations and 14 patients (45.2%) had at least one identical ctDNA alteration that was concordant with tissue DNA. The most commonly altered genes (in both ctDNA and tissue DNA) were TP53 and EGFR. Breast cancer had both the highest proportion of patients with  1 ctDNA alterations (92.3%) and the highest proportion of patients who had  1 alterations in common with tissue DNA (61.5%). 23 of the 25 patients (92%) with detectable ctDNA alterations had additional alterations not found in tissue DNA, which increased with time from tumor DNA sampling. Median time between ctDNA extraction and tissue biopsy was 6.5 months for cases with common alterations, and 12.4 months for those without common alterations. There was trend to decreased OS with increasing ctDNA burden. Conclusions', ' We found that ctDNA is comparable with tissue DNA sequencing in patients with brain metastases. This concordance decreases with increasing time from tissue diagnosis, reflecting the changing nature of tumor genetics and highlighting the utility of ctDNA as a feasible way to monitor changes and identify additional potentially targetable alterations.']",
        "Doc_id":"ASCO_194957-199",
        "Doc_title":" Comparison of tissue DNA to circulating tumor DNA in patients with brain metastases.",
        "_version_":1606189039194472449},
      {
        "Meeting_name":" Rapid and efficient large-scale somatic mutation validation approaches for cancer genome sequencing",
        "Background":"['The landscape of somatic alterations in cancer is being rapidly uncovered by large-scale cancer genome sequencing projects in individual laboratories as well as consortia such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC). The decreasing cost of sequencing has resulted in an increase in the number of cancer genomes that are being sequenced, and thus the numbers of candidate somatic mutations being identified are rapidly expanding. A single cancer genome from a cancer with an average mutation background rate, such as ovarian or breast cancer, will have 3000-6000 mutations. A high mutation rate cancer such as melanoma or colon cancer can have as many as 100,000 mutations/genome. Multiplying these numbers by the dozens of sequenced genomes and hundreds of sequenced exomes across a wide spectrum of tumor types yields a staggering number of candidate mutations. However, approaches for rapidly validating these findings at scale have been lagging behind. Current approaches, such as custom designed hybrid capture arrays followed by sequencing, can take months to complete and cannot begin until the initial sequencing is complete and mutations are called. This can lead to long delays in the interpretation and publication of biological findings. Here we describe the results of several approaches for rapid and efficient validation on large-scale projects, such as TCGA. We will share our approach and results using Fluidigm and PacBio sequencing for validation and sample extension at a small scale with rapid turnaround where we have validated PIK3CA and TP53 mutations in breast cancer samples of varying purity as well as significantly mutated genes in medulloblastoma. Ideally one could validate mutations and gene fusions concurrent with their discovery. To that end, we will also describe our validation results using RNA-Seq data, commonly produced concurrently with genome and exome sequencing, in lung squamous and renal cancer. Finally, we will explore an approach for instant-validation through simultaneous sequencing of barcoded discovery and cross-validation libraries.']",
        "Doc_id":"AACR_2012-3960",
        "Doc_title":" Rapid and efficient large-scale somatic mutation validation approaches for cancer genome sequencing",
        "_version_":1606189040104636416},
      {
        "Meeting_name":" Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC).",
        "Background":"['Background', ' Mutations in DNA repair pathway were identified in 13% of Biliary Tract Cancers (BTC) [Cancer2016;122', '38383847]. High TMB tumors including melanoma, lung cancer and those with microsatellite instability (MSI-H) are associated with susceptibility to immune blockade using checkpoint inhibitors. TMB data in BTC is limited and its association with actionable somatic mutation (mut) profiles in BTC is unknown. Methods', ' Comprehensive genomic profiling (CGP) of 309 FFPE tissue blocks of BTC pts with a hybrid capture of all coding exons of 236 cancer-related genes and 47 introns of 19 genes rearranged in cancer was done using FoundationOne. Base substitutions, indels, gene fusion/rearrangements, TMB, and MSI status were assessed. TMB was calculated by counting mutations across a 1.25Mb region and classified into high (TMBH20 mut/Mb), intermediate (TMBI; 6 - 19mut/Mb) and low (TMBL< 6mut/Mb). MSI high (MSIH) and Stable (MSS) status was assigned by a computational algorithm examining 114 intronic homopolymer loci. Patients with TMB 6 mut/Mb (N = 60) were included in the clinical correlative portion of this study. Results', ' Sixty patients with TMB 6 mut were identified out of 309 pts of which 9 (15%) were TMBH and 51 (85%) were TMBI. These included 3 (5%) MSIH and 18 (30 %) MSS. The median age was 59 years (range', ' 29-86), 35 (58%) were females, majority were intrahepatic cholangiocarcinoma (n = 31; 52%) and 28 (47%) presented with advanced disease at diagnosis. Twenty three (38%) pts had received radiation therapy, 28 (47%) surgery and 3 (5%) received immunotherapy. Most frequent co-existing mut seen was TP53 (N = 35; 58%). APC mut was seen in 7 (12%) pts. DNA repair pathway muts (MSH6, BRCA1,BRCA2, ATM, MLH1, or MSH2 genes) were identified in 78% of TMBH versus 16% in TMBI cases (p < 0.0001). Frequency of PIK3CA mut differed significantly between TMBH and TMBI (44% vs 10%, p < 0.0001). Pts with TMBI had a significantly better median OS (110 weeks) as compared to TMBH (43 weeks) (p = 0.003). Conclusions', ' DNA repair pathway and PIK3CA mut maybe associated with TMBH in BTC. A better understanding of TMB and associated actionable mutations in BTC may be of value for the management of BTC patients with targeted agents and immunotherapy.']",
        "Doc_id":"ASCO_190853-199",
        "Doc_title":" Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC).",
        "_version_":1606188991775768576},
      {
        "Meeting_name":" Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).",
        "Background":"['Background', ' Immunotherapy (IO) has brought dramatic clinical benefit to patients with NSCLC. Most patients tolerate IO, but serious irAE have been reported. In melanoma, a correlation between development of irAE and clinical benefit has been suggested. For NSCLC, the risk of irAE including pneumonitis has been described in clinical trials but not for the wider population. Risk factors for irAE and the impact of irAE on OS are unknown. Methods', ' A retrospective review of patients with NSCLC treated with single-agent IO between September 2014 and June 2016 was carried out at The Ohio State University. Patients had confirmed pathologic disease and received IO either on clinical trial or as standard of care. IrAE were assessed based on the treating physician diagnosis. OS was calculated from the date of initiation of IO to death from any cause or date or last follow-up. Results', ' A total of 90 patients met criteria. Median age was 67. Histology was nonsquamous in 58 (64%) and squamous in 32 (35%). Most patients received nivolumab (n = 87). Median months of IO was 2.6 (95% CI 1.9  4.2). IrAE occurred in 24 patients (26.67%). The most common irAE were pneumonitis (n = 8), thyroid dysfunction (n = 6), and rash/pruritus (n = 5). Other irAE included colitis in 2 patients and new onset diabetes and autoimmune hepatitis in 1 patient each. Development of pneumonitis did not have a statistically significant impact on overall survival (median OS 5.8 vs 8.1 months, p = 0.11). Prior thoracic radiation (TR) was not associated with pneumonitis (11.54% vs 8.33%, p = 0.69), but was associated with shorter survival (median OS 3.9 vs 8.7 months, p = 0.018). Development of irAE was not associated with histology (p = 1.00), KRAS mutation (p = 0.10), TP53 mutation (p = 0.09), or recent flu vaccination (p = 1.00). Patients with irAE had longer median OS (13.2 vs 5.8 months, p = 0.018). Conclusions', ' The incidence of irAE and pneumonitis match that seen in published clinical trials. The development of irAE was associated with better prognosis, whereas patients with prior TR had worse outcomes. Further prospective research is warranted to investigate the correlation of irAE with clinical benefit from IO in patients with NSCLC.']",
        "Doc_id":"ASCO_190090-199",
        "Doc_title":" Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC).",
        "_version_":1606188996467097600},
      {
        "Meeting_name":" An uncharacterized mechanism of cell death independent of p53 mutation status.",
        "Background":"['Resistance to chemotherapeutic agents is often a rate-limiting event in the treatment of metastatic cancers. Mutations of TP53 or dysfunctions in the p53 pathway are known to play primary roles in the resistance to apoptosis-inducing agents. A stapled alpha-helical p53 peptide (SAH-p53) capable of disrupting the p53-HDM2 and p53-HDMX complexes and restoring p53 function has been found to induce a death response in breast, melanoma and choriocarcinoma cancer cells independent of p53 mutational status. We have recently discovered that the mechanism of death induced by SAH-p53 does not exhibit all of the characteristics of classical apoptosis, necrosis or autophagy independently. The binding of SAH-p53 to HDM2, HDMX, or a yet unidentified target results in a mechanism that leads to the intracellular aggregation of proteins and lipids that are extruded from the cell, resulting in catastrophic damage to the integrity of the cell membrane and culminating in cell death. This type of cell death involves the loss of cytoplasm, generation of phase-clear vacuole-like structures, apparent degradation of cellular membrane components, and the significant release of uniform non-vesicular cellular components. The cellular debris, while yet undefined, displays orange staining with acridine orange as well as accumulation of MitoTracker, suggesting that the debris contains hydrophobic regions. Thus far it has been established that there is a lack of any membrane blebbing, no chromatin condensation, no apoptosis signaling events or typical necrotic bubble formation after treatment with SAH-p53 in cells harboring wild-type p53, mutant p53, or null p53, suggesting an alternative mechanism of cell death. Data suggest the manifestation of early autophagy within 6 hours of SAH-p53 treatment as evidenced by LC3 accumulation, yet this phenotype is lost within 24 hours post-treatment. In addition, the pretreatment of the cells with chloroquine does not inhibit the release of debris and changes in morphology characteristic of SAH-p53 treatment, suggesting that the mechanism of death is independent of classical autophagy. We have begun to uncover the precise mechanism of cell death through the identification and validation of the transcriptional program regulated by SAH-p53 in both wild-type and mutant p53-containing cells via microarray analysis. The complete understanding and characterization of this novel mechanism may be exploited to overcome resistance to apoptosis and thus lead to a more effective way of treating chemotherapy-resistant metastatic cancers.']",
        "Doc_id":"AACR_2013-839",
        "Doc_title":" An uncharacterized mechanism of cell death independent of p53 mutation status.",
        "_version_":1606189018524942336},
      {
        "Meeting_name":" Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas",
        "Background":"['Introduction', \" In 2014, TCGA's Bladder Cancer Working Group presented a preliminary integrated molecular analysis of 131 muscle-invasive urothelial carcinomas (Nature 507\", '315, 2014). We now report on the entire cohort of 412 fresh-frozen, chemotherapy-nave tumors. Included in the analysis were paired blood and/or tumor-adjacent tissue samples. This is the largest sequencing project on bladder cancer to date. After strict clinical and pathologic quality control, tumors were analyzed for DNA copy number variants, somatic mutations, DNA methylation, mRNA, microRNA and (phospho-) protein expression, transcript splicing, gene fusions, viral integration, APOBEC mutagenesis, pathway perturbation, clinical correlates, and histopathology.Results', ' There was a high overall somatic mutation rate (8.0/Mb), with a median of 245 and mean of 348 coding-region mutations per sample. That is the third highest mutation rate among the cancer types profiled by TCGA (after cutaneous melanoma and non-small cell lung cancers). We identified 54 genes as significantly mutated, compared with 32 in the original report on 131 tumors. TP53 mutations were the most common (49%), and also quite common were mutations in a number of chromatin-modifying genes, including MLL2 (29%), KDM6A (26%), ARID1A (25%), MLL3 (19%), EP300 (15%), CREBBP (12%), and MLL (11%). Other cancer-related genes showing frequent mutations included PIK3CA (22%), RB1 (17%), FGFR3 (14%), STAG2 (14%), ATM (14%), ELF3 (12%), FAT1 (12%), SPTAN1 (12%), ERBB2 (12%), ERBB3 (11%), ASXL2 (10%), ERCC2 (9%), CDKN1A (9%), TSC1 (8%), CDKN2A (7%), RHOB (6%), NFE2L2 (6%), PARD3 (6%), FAM47C (5%), RBM10 (5%),HRAS (5%), KRAS (4%), and PTEN (3%). High mutation burden was associated with improved outcome (p = 0.0004). APOBEC mutagenesis explained 70% of the mutation burden and was associated with survival. Gene silencing by promoter hypermethylation was identified in 167 genes with at least 5% frequency in the cohort. The previously identified four mRNA expression subtypes were again found in the complete set of 412 tumors, and the proportions of samples in each subtype were similar to the previous proportions. Reverse-phase proteomic array analysis of 344 of the samples revealed clusters associated with diagnostic subtype, pathological stage, and grade but not with smoking history or non-muscle invasive status.Conclusions', ' This integrated molecular analysis of 412 TCGA tumor samples largely validates and considerably extends observations from the initial cohort of 131 patients. The larger cohort significantly increased our power to detect lower-frequency aberrations that were not identified in the original cohort. The results provide a robust basis for further functional studies of bladder cancer biology and also provide additional incisive information for the identification of molecular targets for therapy.']",
        "Doc_id":"AACR_2016-128",
        "Doc_title":" Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas",
        "_version_":1606188971698683904},
      {
        "Meeting_name":" Subtyping of pancreatic cancer patient-derived xenograft tumors and implications for anticancer agent testing",
        "Background":"['Despite improvements in treatment, pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with a continuous increase in incidence emphasizing the need for further research and therapeutic development. In recent years, we have developed a collection of >40 patient-derived xenograft (PDX) models from PDAC. In order to determine their relevance for anticancer agent testing, we extensively characterized our models for histology features, whole exome mutations (Hiseq 2000), chromosome rearrangements, gene copy number variations (Affymetrix SNP6) and gene expression (Affymetrix U133 Plus2.0).PDAC from 65 patients were implanted into immuno-compromised mice, resulting in the development of 42 PDX models (success rate 65%). The PDAC from which models were established included moderate and poorly differentiated tumors and were heterogeneous for stroma content. In patient tumors, we showed fibroblast activation but not stroma content predicted poor patient outcome (p<0.0001) and success of PDX establishment (p<0.01). Correlating with those of the parental tumors, the resulting PDAC_PDX also showed heterogeneity for stroma content and for murine fibroblast activation. As seen in patient tumors, the PDAC_PDX were characterized by frequent chromosomal instability, with 38% of the models presenting a moderate hypoploidy while the 62% remaining ones showed a hyperploidy. Two models showed hypermutation due to mismatch repair deficiency while the others had on average a lower mutation load when compared to other histotypes such as colon, lung or melanoma tumors. In total, we identified more than 9000 genes altered by homozygous deletions, high gene amplifications and/or mutations, most of the models showed alterations in KRAS (81%), TP53 (67%), CDKN2A (64%) and TGFBR2/SMAD4 (64%) genes. Next, PDAC_PDX profiles were merged with those of patient tumors to determine PDAC_PDX subtypes and were found to be of the classical (61%), quasi mesenchymal (QM) (34%) and exocrine like subtype (5%) according to the 62 gene expression signature established by Collisson et al. 2011. Preliminary biomarker analysis revealed certain associations between genomic alterations and transcriptome subtypes, such as more frequent alterations in the TGFB pathway in classical PDX (80%) compared to QM (47%). Further detailed biomarkers analyses also addressing questions of molecular determinants of stroma content, of fibroblast activation and of sensitivity toward anticancer agents will be presented.Extensive characterization of our PDAC_PDX collection revealed similarities with patient tumors with regards of histology features including stroma content and fibroblast activation. At molecular level, the models showed similar genomic and transcriptomic patterns as those reported for patient PDAC, altogether, proving the value of this collection for drug development investigations.']",
        "Doc_id":"AACR_2016-639",
        "Doc_title":" Subtyping of pancreatic cancer patient-derived xenograft tumors and implications for anticancer agent testing",
        "_version_":1606189027478732800},
      {
        "Meeting_name":" Uncovering signals of somatic selection through whole exome and whole genome sequencing of lung adenocarcinoma",
        "Background":"['We have sequenced the exomes of over 100 and the genomes of over 20 lung adenocarcinoma tumor-normal specimen pairs. We performed hybrid capture exome sequencing of nearly 18,000 genes to >100X median per-sample coverage with 76bp paired-end reads. We performed whole genome sequencing achieving 60X median tumor and 20X median normal coverage with 350bp median insert size and 101bp paired-end reads. Our exome analysis yielded over 50,000 substitution and small indel coding events, with a mean somatic mutation rate of 10-11 events / MB. This resulted in over 300 non-synonymous coding events per patient, most of which were presumed to be passenger mutations unrelated to tumorigenesis. This high mutational load required us to develop novel statistical approaches (MutSig, Lawrence et al, in preparation) to identify putative lung adenocarcinoma driver genes under positive somatic selection. We constructed a complex neutral mutation model that considered sequence context and several additional genomic covariates shown to mediate gene to gene inhomogeneities of passenger mutation rates. Identification of significant deviations from this background model allowed us to recover almost all known frequently mutated lung adenocarcinoma genes, including TP53, KRAS, STK11, PIK3CA, EGFR, ERBB2, RB1, SMARCA4, and KEAP1, as well as a host of novel putative driver genes. We applied similar principles to identify pathways and sub-networks of genes undergoing apparent positive selection in lung adenocarcinoma. Whole genome analysis yielded several high-confidence in-frame protein fusion and promoter-gene fusion events enriched in tumor vs normal specimens. We also found large numbers of somatic substitution and indel events in promoters, enhancers, and non-coding DNA elements and identified putative sites of somatic retrotransposition in our whole genome data. Overall, our study eclipses previous large-scale characterization of somatic sequence variation (Refs. 1-3) in lung adenocarcinoma by at least an order of magnitude. Using novel methods adapted to the analysis of high-mutation rate tumor types (lung squamous cell carcinoma, melanoma, colorectal cancer), we are able to recover signals of selection in both known and novel genes and pathways. Our results illuminate novel lung adenocarcinoma tumor biology and provide targets for therapeutic and diagnostic investigation. References 1. Ding et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) vol. 455 (7216) pp. 1069-75 2. Kan et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) vol. 466 (7308) pp. 869-73 3. Lee et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) vol. 465 (7297) pp. 473-7']",
        "Doc_id":"AACR_2012-1682",
        "Doc_title":" Uncovering signals of somatic selection through whole exome and whole genome sequencing of lung adenocarcinoma",
        "_version_":1606189036532137984},
      {
        "Meeting_name":" Implementing an automated clinical next generation sequencing analysis pipeline - assuring accurate and robust results.",
        "Background":"['Introduction', ' There is unmet clinical need for automated data processing of deep sequencing in heterogeneous sample populations in molecular oncology specimens. We have developed clinical assays using Next Generation Sequencing (NGS) for deep sequencing in both solid tumor and hematological indications. We have targeted five genes (ASXL1, RUNX1, EZH2, ETV6, and TP53) involved in myelodysplastic syndrome (MDS) and three genes (BRAF, c-KIT, NRAS) in late stage melanoma. We designed and implemented a data processing pipeline that integrates novel and commercial analysis software to provide automated rules-based filtering and annotation of variants.Methods', ' We used a targeted resequencing approach with the Fluidigm Access Array system for library creation and molecular barcoding for sample multiplexing. Samples were processed in duplicate to filter out potential false positives. Libraries were sequenced using the Ion Torrent Personal Genome Machine (PGM) (Life Technologies, Carlsbad, CA) and the Illumina MiSeq (Illumina Inc., San Diego, CA) systems. Raw data in FastQ format was preprocessed using Windows batch commands and Perl programs that were integrated with NextGENe (SoftGenetics, State College, PA) analysis software for quality trimming, alignment and variant calling against NCBI curated references. Variant calls were compared between duplicate samples and annotated using a separate Perl program that queried databases containing known germline and somatic variants.Results', ' Quality control was implemented by trimming all downstream reads that contained specified Q-scores (Phred, Q16 or above) as well as requiring a minimum coverage depth of 500X per exon. Only variant calls confirmed at greater than 5% in both duplicate samples and with a balanced ratio of forward and reverse reads were considered reportable in a clinical setting. Variants appearing in only one of the duplicates were consistent with systematic errors. Variant calls were annotated with existing database information or were saved in a database of novel mutations by the annotation pipeline. The pipeline removes all systematic errors in known cell line samples by filtering metrics.Conclusions', ' We have developed a robust and automated pipeline for NGS data analysis in the clinical lab that is independent of sequencing platform. The implementation of an automated processing pipeline increases the efficiency and consistency of analysis. Hands-on time for data analysis has been decreased from 30 minutes per sample to less than 5 minutes per sample. Carrying duplicates through the entire multiplexing and sequencing process also helps reduce test based false-positive errors (e.g. PCR errors) while robust analytical metrics remove other sources of error (e.g. strand bias). We have found an average of 6-10 false positive calls in both sample types, all of which were filtered out by the pipeline presented here.']",
        "Doc_id":"AACR_2013-5137",
        "Doc_title":" Implementing an automated clinical next generation sequencing analysis pipeline - assuring accurate and robust results.",
        "_version_":1606189041938595840},
      {
        "Meeting_name":" Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US",
        "Background":"[\"Commercial genomic and protein-based profiling was performed on tissue from pancreatic cancer patients who enrolled in the Pancreatic Cancer Action Network's Know Your Tumor (KYT) service. The service offers molecular profiling for patients with resectable or metastatic disease, in preparation for their next treatment plan. Patients are eligible to enroll at any institution, clinic, or cancer center in the US. Biopsies, tissue retrieval and testing is coordinated by Perthera, Inc.From 6/2014 to 11/2015 tumor biopsies, resected or archived tissue was obtained from 152 (53% male) pancreatic cancer patients and profiling including NGS/FISH (144 patients) and IHC (143 patients) was performed. The median age at biopsy or resection was 63 (25-83), 55% of the tissue came from liver, 16% from pancreas, 7% lung, 4% peritoneum, and 18% from another type of tissue. 87% of the patients were diagnosed with pancreatic ductal adenocarcinoma and the remaining with another form of confirmed or suspected pancreatic cancer.The most identified pathogenic mutations were KRAS (85%), TP53 (72%), CDKN2A (47%), CDKN2B (24%), SMAD4 (22%), ARID1A (10%), STK11 (7%), and BRCA2 (5%). The average number of genomic alterations (likely but not confirmed to be somatic) detected was five per patient from a panel of 320 genes. Molecular modifications that are linked to a treatment option were observed in 44% of patients. Twenty four of 144 patients (17%) had mutations in at least one DNA repair gene potentially benefiting from platinum or PARP inhibitor-based therapies, including BRCA2 (5%), ATM (4%), BAP1 (4%), SMARCA4 (3%), FANC (1%), CHEK2 (1%), and PALB2 (<1%). Other actionable molecular phenotypes observed include anti-HER2 therapies targeting ERBB2 amplifications (3%) and mTOR inhibitors suitable for patients with mutations in STK11/LKB1 (7%), PTEN (3.5%), PIK3R1 (<1%), or PIK3CA (3%). Actionable alterations identified with a low frequency (<2%) include RET fusions, amplifications of FGFR, CRKL, AXL, and mutations in NTRK3, MEN1 (PNET), and BRAF. One patient harbored the BRAF V600E mutation, prompting consideration of off label melanoma-approved therapy. Overexpression of ALK by IHC was observed in one patient who chose to enroll in a ceritinib clinical trial. Six percent of patients were PDL-1 positive, and 22% were positive for PD-1 from tumor infiltrating lymphocytes, suggesting possible activity from immune checkpoint inhibitors.To date, 7 of the 152 patients have enrolled in a clinical trial, 4 were treated with an off label treatment, 67 have yet to make their next treatment decision, and 53 are known to be deceased. KYT has successfully profiled tumors and presented targeted treatment options to patients and physicians in 33 states regardless of a patient's socioeconomic background and geographic location, moving the field a step closer towards a democratized, personalized approach to treating pancreatic cancer.\"]",
        "Doc_id":"AACR_2016-93",
        "Doc_title":" Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US",
        "_version_":1606189020780429312},
      {
        "Meeting_name":" Liquid biopsy using the ion AmpliSeq v2 cancer panel",
        "Background":"['Introduction', 'Plasma cell-free circulating tumor DNA (ctDNA) has the potential to serve as a noninvasive surrogate to determine tumor genotype and monitor treatment response. Here we report the analytical validation of the Ion AmpliSeq v2 Cancer Panel (ACP) in plasma ctDNA samples.Methods', 'Mutations were assessed using the ACP, designed to survey 2800 mutations in 50 cancer-related genes. TruQ reference standards were used to determine LOD. Healthy donor and cancer patient plasma samples were used for other studies. Eight libraries were barcoded and sequenced with PGM sequencing 200 kit v2 on a 318 v2 chip. The sequencing data were analyzed with a combination of Torrent Suite 3.4.2, VarScan, our proprietary analysis pipeline and IGV. The background noise level of hotspot nt positions was calculated from multiple runs of known wild type DNA. In order to increase the sensitivity of the assay to detect low-level mutation, a custom program was developed to detect variants clearly different from background noise (95% confidence) and not reported by the two variant callers. PCR methods were used for concordance testing.Results', 'The performance characteristics of the AmpliSeq v2 Cancer Panel were demonstrated in 1) Minimum DNA input and LOD', ' With 10 ng DNA input, 43/43 and 42/43 expected mutations were detected at 2.5% or 1%, respectively. With 1 ng DNA input, 42/43 and 40/43 expected mutations were detected at 2.5% and 1%, respectively. 2) Coverage', ' The mean library coverage for 40 plasma libraries was 2912x with only 5 non-critical regions below 250x coverage. 3) Baseline error rate', ' 95% of 2290 hot-spots for SBS showed <0.5% background error frequency assessed in 10 healthy control ctDNA samples. The mean background error frequency plus two folds of SD falls below 0.5% for 91% of SBS hot-spots. 4)Precision', ' All mutations expected for TruQ6 were detected in 4 independent runs at observed allele frequencies with 0.6% mean SD and 0.1% mean deviation from the true value. A 2% TP53 mutation R174W was reproducibly detected in a lung cancer plasma sample in 2 independent runs. 5) Concordance study', ' Consistent results were observed for 3 positive (Allele Freq 40%, 3% and 0.2%, respectively) and 3 negative melanoma plasma samples previously genotyped by AS-PCR for Braf V600E/K mutations. Additional cancer patient ctDNA samples are being assessed for concordance in the detection of other mutations.Conclusions', 'The ACP offers a useful tool for comprehensive somatic mutation profiling in ctDNA. The limit of detection is 1-2% mutation frequency for most mutations with slight variation across different nucleotide positions. The low concentration of ctDNA obtained from plasma samples can present a challenge. Less than 10 ng DNA input may result in allele drop out for low level mutations due to the inefficient amplification of multiplex PCR compared with PCR methods using a short length single amplicon. Higher DNA input to rescue allele drop-out is under evaluation.']",
        "Doc_id":"AACR_2015-4925",
        "Doc_title":" Liquid biopsy using the ion AmpliSeq v2 cancer panel",
        "_version_":1606188992402817024}]
  }}
